

Trastuzumab Emtansine for Residual Invasive HER2-Positive

New England Journal of Medicine

380, 617-628

DOI: [10.1056/nejmoa1814017](https://doi.org/10.1056/nejmoa1814017)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Inflammatory Breast Cancer: a Separate Entity. <i>Current Oncology Reports</i> , 2019, 21, 86.	1.8	23
3	Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. <i>Annals of Oncology</i> , 2019, 30, 1541-1557.	0.6	464
4	A Review of Local and Systemic Therapy in Breast Cancer. , 2019, , 637-690.		0
5	A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1721-1730.	1.9	47
6	Identification of the Bacterial Maytansinoid Gene Cluster <i>asc</i> Provides Insights into the Post-PKS Modifications of Ansacarbamitocin Biosynthesis. <i>Organic Letters</i> , 2019, 21, 5823-5826.	2.4	4
7	Does Tumor Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2019, 19, e741-e747.	1.1	19
8	Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2019, 37, 2196-2200.	0.8	4
9	The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine. <i>Annals of Oncology</i> , 2019, 30, 1183-1184.	0.6	18
10	PERSEPHONE - implications for clinical practice in 2019. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 663-664.	12.5	1
11	Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis. <i>Annals of Surgical Oncology</i> , 2019, 26, 3517-3525.	0.7	29
12	Sentinel Node Lymph Node Surgery After Neoadjuvant Therapy: Principles and Techniques. <i>Annals of Surgical Oncology</i> , 2019, 26, 3040-3045.	0.7	9
13	Interim [18F]Fluorodeoxyglucose-Positron Emission Tomography During Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2091-2092.	0.8	1
14	Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers. <i>Lancet Oncology</i> , The, 2019, 20, e390-e396.	5.1	63
15	Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 312-314.	0.3	1
16	Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 4337-4345.	0.7	29
17	An engineered antibody fragment targeting mutant β -catenin via major histocompatibility complex I neoantigen presentation. <i>Journal of Biological Chemistry</i> , 2019, 294, 19322-19334.	1.6	15
18	Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1079-1089.	0.8	18
19	Breast cancer statistics, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 438-451.	157.7	2,068

#	ARTICLE	IF	CITATIONS
20	Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy – German Experts’ Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019). <i>Breast Care</i> , 2019, 14, 315-324.	0.8	9
21	What therapies are on the horizon for HER2 positive breast cancer?. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 811-822.	1.1	3
22	A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 647-656.	1.1	16
24	Adjuvant Short-Course Trastuzumab in Breast Cancer. <i>Indian Journal of Gynecologic Oncology</i> , 2019, 17, 1.	0.1	2
25	New strategies for the precision treatment of HER2-driven tumours. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 239-249.	0.4	0
26	Real-world data on T-DM1 efficacy – results of a single-center retrospective study of HER2-positive breast cancer patients. <i>Scientific Reports</i> , 2019, 9, 12760.	1.6	17
27	Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer. <i>Future Oncology</i> , 2019, 15, 2489-2501.	1.1	8
28	Yangpunicins F and G, Eneidyne Congeners from <i>Micromonospora yangpuensis</i> DSM 45577. <i>Journal of Natural Products</i> , 2019, 82, 2483-2488.	1.5	23
29	A promising cancer diagnosis and treatment strategy: targeted cancer therapy and imaging based on antibody fragment. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 3621-3630.	1.9	8
30	Antibody–drug conjugates for cancer. <i>Lancet, The</i> , 2019, 394, 793-804.	6.3	425
31	St Gallen International Consensus Guidelines in early breast cancer: experts to prevent patients’ overtreatment and breaking the bank?. <i>Annals of Oncology</i> , 2019, 30, 1533-1535.	0.6	3
32	The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 866.	1.3	25
34	Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis. <i>Cancer Management and Research</i> , 2019, Volume 11, 8043-8054.	0.9	1
35	Targeted therapeutic options and future perspectives for HER2-positive breast cancer. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 34.	7.1	242
36	Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7388-7395.	3.2	12
37	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. <i>Breast Care</i> , 2019, 14, 224-245.	0.8	72
38	GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses. <i>Cell Reports</i> , 2019, 28, 3367-3380.e8.	2.9	37
39	Breast cancer. <i>Nature Reviews Disease Primers</i> , 2019, 5, 66.	18.1	1,620

#	ARTICLE	IF	CITATIONS
41	Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 591-604.	0.8	20
42	Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 3502-3509.	0.7	61
43	Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial?. <i>European Journal of Cancer</i> , 2019, 117, 1-4.	1.3	2
44	Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an "option" but an ethical obligation. <i>ESMO Open</i> , 2019, 4, e000515.	2.0	12
45	HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology. <i>Journal of Geriatric Oncology</i> , 2019, 10, 1003-1013.	0.5	40
46	Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. <i>Lancet Oncology</i> , The, 2019, 20, 1124-1135.	5.1	339
47	A new agent in the family of antibody"drug conjugates. <i>Lancet Oncology</i> , The, 2019, 20, 1043-1044.	5.1	0
48	6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. <i>Lancet</i> , The, 2019, 393, 2599-2612.	6.3	225
49	Is the duration of adjuvant trastuzumab debate still clinically relevant?. <i>Lancet</i> , The, 2019, 393, 2565-2567.	6.3	5
50	Update Breast Cancer 2019 Part 1 "Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 256-267.	0.8	17
51	Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 61-66.	1.1	42
54	Therapeutic innovations in breast cancer. <i>Presse Medicale</i> , 2019, 48, 1131-1137.	0.8	5
55	Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2"Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2206-2216.	0.8	152
56	Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2"Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2189-2192.	0.8	12
57	Update Breast Cancer 2019 Part 3 "Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 470-482.	0.8	26
58	Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1194-1220.	0.6	1,241
59	6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. <i>Lancet</i> , The, 2019, 393, 2591-2598.	6.3	102
61	Debating the Optimal Approach to Nodal Management After Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 42-48.	1.8	9

#	ARTICLE	IF	CITATIONS
62	More options for adjuvant treatment of HER2-positive breast cancer: How to choose wisely?. <i>International Journal of Cancer</i> , 2019, 145, 2901-2906.	2.3	10
63	Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 6026-6034.	3.2	50
64	Cancer metabolomic markers in urine: evidence, techniques and recommendations. <i>Nature Reviews Urology</i> , 2019, 16, 339-362.	1.9	99
65	Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 447-454.	1.1	8
66	Cardiotoxicity of Contemporary Breast Cancer Treatments. <i>Current Treatment Options in Oncology</i> , 2019, 20, 51.	1.3	16
67	Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore. <i>Clinical Cancer Research</i> , 2019, 25, 4985-4992.	3.2	17
68	Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, e190339.	3.4	55
70	Sentinel Node Biopsy After Neoadjuvant Systemic Therapy for Breast Cancer: The Method Matters. <i>Annals of Surgical Oncology</i> , 2019, 26, 2316-2318.	0.7	2
71	ER+/HER2+ breast cancer: are we really de-escalating?. <i>Annals of Oncology</i> , 2019, 30, 875-877.	0.6	4
72	Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. <i>Biomarker Research</i> , 2019, 7, 9.	2.8	19
73	Highlights of the 16th St Gallen International Breast Cancer Conference, Vienna, Austria, 20-23 March 2019: personalised treatments for patients with early breast cancer. <i>Ecancermedicalsecience</i> , 2019, 13, 924.	0.6	19
74	Acquired Resistance to Antibody-Drug Conjugates. <i>Cancers</i> , 2019, 11, 394.	1.7	89
75	Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591982771.	1.4	38
76	HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1115.	1.8	144
77	St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment. <i>Breast Care</i> , 2019, 14, 103-110.	0.8	131
78	De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 1099-1104.	1.1	5
79	Pertuzumab in HER2-positive early breast cancer: current use and perspectives. <i>Future Oncology</i> , 2019, 15, 1823-1843.	1.1	14
80	Pharmacotherapeutic options for patients with refractory breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 851-861.	0.9	3

#	ARTICLE	IF	CITATIONS
81	Further Progress for Patients with Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 676-677.	13.9	13
82	In the literature: April 2019. <i>ESMO Open</i> , 2019, 4, e000513.	2.0	0
86	Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm. <i>Current Breast Cancer Reports</i> , 2019, 11, 248-258.	0.5	2
90	Editorial: Optimizing treatment strategy in early breast cancer: less is more, or more is better?. <i>Current Opinion in Oncology</i> , 2019, 31, 469-471.	1.1	1
91	When to Add Additional Anti-HER2 Therapy to Adjuvant Trastuzumab. <i>Current Oncology Reports</i> , 2019, 21, 109.	1.8	3
92	Inflammatory Breast Cancer: Diagnostic, Molecular and Therapeutic Considerations. <i>Current Breast Cancer Reports</i> , 2019, 11, 335-346.	0.5	2
93	Trastuzumab-Induced Cardiomyopathy. <i>Cardiology Clinics</i> , 2019, 37, 407-418.	0.9	47
94	Recent Developments in HER2-Directed Therapy in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2019, 11, 311-325.	0.5	0
95	Risk stratification according to stage and pathology. <i>Breast</i> , 2019, 48, S23-S25.	0.9	2
96	Research priorities in prediction of response in early breast cancer. <i>Breast</i> , 2019, 48, S31-S33.	0.9	1
97	Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease. <i>Breast</i> , 2019, 48, S49-S52.	0.9	4
98	Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer. <i>Breast</i> , 2019, 48, S97-S102.	0.9	6
99	Breast cancer survivorship care beyond local and systemic therapy. <i>Breast</i> , 2019, 48, S103-S109.	0.9	10
100	Will surgery be a part of breast cancer treatment in the future?. <i>Breast</i> , 2019, 48, S110-S114.	0.9	3
101	Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 2180.	1.0	12
102	Systemic treatment of patients with early breast cancer: recent updates and state of the art. <i>Breast</i> , 2019, 48, S7-S20.	0.9	21
103	Monoclonal Antibodies: Past, Present and Future. <i>Handbook of Experimental Pharmacology</i> , 2019, 260, 81-141.	0.9	41
104	T-DM1 protects against invasive disease. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 145-145.	12.5	1

#	ARTICLE	IF	CITATIONS
105	Truly personalized therapy â€” an end to the era of one size fits all. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 77-78.	12.5	8
106	Neoadjuvant chemotherapy in nonâ€”metastatic breast cancer: a study on practice trends in a regional cancer treatment service. <i>Internal Medicine Journal</i> , 2020, 50, 315-321.	0.5	4
107	HER2-targeted therapies â€” a role beyond breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 33-48.	12.5	569
108	Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 101-111.	1.1	17
109	A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, e251-e260.	1.1	15
110	Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab. <i>Oncology</i> , 2020, 98, 35-41.	0.9	4
111	Regenerative nodular hyperplasia after T-DM1: consequences from sinusoidal endothelium damages. <i>Acta OncolÃ³gica</i> , 2020, 59, 306-309.	0.8	4
112	Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2â€”Directed Chemotherapy in HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 19-24.	1.1	24
113	Reply to the Correspondence by Untch et al. â€œConcerning Dediu M, Zielinski C: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancerâ€”[<i>Breast Care</i> 2019; DOI 10.1159/000500624]. <i>Breast Care</i> , 2020, 15, 314-316.	0.8	0
114	HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibodyâ€”Drug Conjugate Drug Development in Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 775-786.	3.2	36
115	Pathologic reporting practices for breast cancer specimens after neoadjuvant chemotherapyâ€”a survey of pathologists in academic institutions across the United States. <i>Modern Pathology</i> , 2020, 33, 91-98.	2.9	7
116	Ultrasound guided tattooing of axillary lymph nodes in breast cancer patients prior to neoadjuvant therapy, and identification of tattooed nodes at the time of surgery. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1041-1045.	0.5	27
117	Associations of Early Medicaid Expansion With Insurance Status and Stage at Diagnosis Among Cancer Patients Receiving Radiation Therapy. <i>Practical Radiation Oncology</i> , 2020, 10, e207-e218.	1.1	12
118	Multicentre prospective observational study evaluating recommendations for mastectomy by multidisciplinary teams. <i>British Journal of Surgery</i> , 2020, 107, 227-237.	0.1	7
119	Overuse of Neo-adjuvant Chemotherapy for Primary Breast Cancer. <i>Indian Journal of Surgical Oncology</i> , 2020, 11, 12-14.	0.3	5
120	Doseâ€”dense adjuvant chemotherapy in HER2â€”positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. <i>International Journal of Cancer</i> , 2020, 147, 160-169.	2.3	12
121	T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study. <i>Clinical Breast Cancer</i> , 2020, 20, e181-e187.	1.1	30
122	Time to initiation of neoâ€”adjuvant chemotherapy for breast cancer treatment does not influence patient survival: A study of US breast cancer patients. <i>Breast Journal</i> , 2020, 26, 625-629.	0.4	8

#	ARTICLE	IF	CITATIONS
123	Long-term quality of life after preoperative radiochemotherapy in patients with localized and locally advanced breast cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 386-397.	1.0	7
124	Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1. <i>Molecular Cancer Research</i> , 2020, 18, 644-656.	1.5	17
125	Reactive stroma and trastuzumab resistance in HER2- ϵ positive early breast cancer. <i>International Journal of Cancer</i> , 2020, 147, 266-276.	2.3	13
126	Concerning Dediu M, Zielinski A: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer. <i>Breast Care</i> 2019; Doi 10.1159/000500620. <i>Breast Care</i> , 2020, 15, 96-101.	0.8	1
127	Refining the indications for neoadjuvant chemotherapy for patients with HER2+ breast cancer: A single institution experience. <i>Journal of Surgical Oncology</i> , 2020, 121, 447-455.	0.8	6
128	Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. <i>Annals of Oncology</i> , 2020, 31, 61-71.	0.6	119
129	Outcomes for Patients with Residual Stage II/III Breast Cancer Following Neoadjuvant Chemotherapy (AFT-01). <i>Annals of Surgical Oncology</i> , 2020, 27, 637-644.	0.7	2
130	Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience. <i>Tumori</i> , 2020, 106, 301-305.	0.6	3
131	Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 529-536.	1.2	37
132	Contemporary Issues in Breast Cancer Radiotherapy. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 1-12.	0.9	5
133	Precision Medicine and Targeted Therapies in Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 51-62.	0.6	32
134	Effects of High Anxiety Scores on Surgical and Overall Treatment Plan in Patients with Breast Cancer Treated with Neoadjuvant Therapy. <i>Oncologist</i> , 2020, 25, 212-217.	1.9	7
135	ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer. <i>Cancer Letters</i> , 2020, 473, 156-163.	3.2	39
136	Identification of potential key genes for HER-2 positive breast cancer based on bioinformatics analysis. <i>Medicine (United States)</i> , 2020, 99, e18445.	0.4	19
137	Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. <i>British Journal of Cancer</i> , 2020, 122, 603-612.	2.9	126
138	Efficacy and safety of tailored and dose- ϵ dense adjuvant chemotherapy and trastuzumab for resected HER2- ϵ positive breast cancer: Results from the phase 3 PANTHER trial. <i>Cancer</i> , 2020, 126, 1175-1182.	2.0	14
139	Towards personalized treatment for early stage HER2-positive breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 233-250.	12.5	166
140	Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 33-43.	5.1	105

#	ARTICLE	IF	CITATIONS
141	Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 3-11.	0.6	7
142	GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells. <i>Oncolmunology</i> , 2020, 9, 1683345.	2.1	54
143	Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients. <i>Cancer Treatment Reviews</i> , 2020, 83, 101944.	3.4	3
144	Axillary ultrasound for prediction of response to neoadjuvant therapy in the context of surgical strategies to axillary dissection in primary breast cancer: a systematic review of the current literature. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 341-353.	0.8	38
145	Validation of the NSABP/NCIC Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa058.	1.4	2
146	De-escalation of Axillary Surgery in the Neoadjuvant Chemotherapy (NACT) Setting for Breast Cancer: Is it Oncologically Safe?. <i>Anticancer Research</i> , 2020, 40, 5351-5354.	0.5	4
147	Real-World Data Analysis of Pregnancy-Associated Breast Cancer at a Tertiary-Level Hospital in Romania. <i>Medicina (Lithuania)</i> , 2020, 56, 522.	0.8	4
148	Targeting HER2 heterogeneity in early-stage breast cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 545-554.	1.1	21
149	Last but not least: antibody-drug conjugates in hormone receptor-positive metastatic breast cancer. <i>Annals of Oncology</i> , 2020, 31, 1594-1596.	0.6	1
150	Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. <i>Lancet Oncology</i> , The, 2020, 21, 1283-1295.	5.1	213
151	The anti-B7-H4 checkpoint synergizes trastuzumab treatment to promote phagocytosis and eradicate breast cancer. <i>Neoplasia</i> , 2020, 22, 539-553.	2.3	12
152	The use of a second core needle biopsy to predict response to neoadjuvant chemotherapy in breast cancer patients, especially in the HER2-positive population. <i>Surgery</i> , 2020, 168, 1115-1121.	1.0	1
153	Landmark trials in the medical oncology management of early stage breast cancer. <i>Seminars in Oncology</i> , 2020, 47, 278-292.	0.8	6
154	Neoadjuvant breast cancer treatment response; tumor size evaluation through different conventional imaging modalities in the NeoDense study. <i>Acta Oncologica</i> , 2020, 59, 1528-1537.	0.8	11
155	Update on breast cancer diagnosis and management: new topics for primary care. <i>British Journal of General Practice</i> , 2020, 70, 515-516.	0.7	0
156	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4184-4193.	0.8	74
157	Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1). <i>Clinical and Translational Radiation Oncology</i> , 2020, 24, 99-101.	0.9	6
158	Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer. <i>JAMA Surgery</i> , 2020, 155, e204103.	2.2	58

#	ARTICLE	IF	CITATIONS
159	Lymphatic immunomodulation using engineered drug delivery systems for cancer immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2020, 160, 19-35.	6.6	27
160	An overview of antibody-drug conjugates in oncological practice. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096299.	1.4	15
161	Identification of NCAPH as a biomarker for prognosis of breast cancer. <i>Molecular Biology Reports</i> , 2020, 47, 7831-7842.	1.0	17
162	Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer. <i>Drugs</i> , 2020, 80, 1723-1730.	4.9	2
163	Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars. <i>Drugs</i> , 2020, 80, 1811-1830.	4.9	23
164	Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1073-1083.	1.3	9
165	Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer. <i>Oncologist</i> , 2020, 25, e1355-e1362.	1.9	8
166	GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain. <i>Oncologist</i> , 2020, 25, e1339-e1345.	1.9	14
167	ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. <i>Cancers</i> , 2020, 12, 1902.	1.7	29
168	Taking a Second Look at Neoadjuvant Endocrine Therapy for the Treatment of Early Stage Estrogen Receptor Positive Breast Cancer During the COVID-19 Outbreak. <i>Annals of Surgery</i> , 2020, 272, e96-e97.	2.1	22
169	Preparing for the Renaissance: Treating Breast Cancer during the COVID-19 Pandemic and Planning for a Safe Re-Emergence to Routine Surgical Care within a Universal Health Care System. <i>Current Oncology</i> , 2020, 27, 163-168.	0.9	7
170	Enhancing the Critical Role of Core Needle Biopsy in Breast Cancer. <i>Hellenike Cheirurgike Acta Chirurgica Hellenica</i> , 2020, 92, 76-84.	0.1	1
171	Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer. <i>Cardio-Oncology</i> , 2020, 6, 26.	0.8	8
172	Update Breast Cancer 2020 Part 3 - Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1105-1114.	0.8	12
173	Trastuzumab-related cardiotoxicity: what do we know in 2020?. <i>Translational Cancer Research</i> , 2020, 9, 4052-4055.	0.4	0
174	Development of CNS metastases in breast cancer patients treated with curative intent: a case-control study. <i>CNS Oncology</i> , 2020, 9, CNS61.	1.2	4
175	Does the Time from Diagnostic Biopsy to Neoadjuvant Chemotherapy Affect the Rate of Pathologic Complete Response in Stages I-III Breast Cancer?. <i>Current Oncology</i> , 2020, 27, 265-270.	0.9	1
176	Neoadjuvant dual anti-HER2 therapy for early breast cancer: where do we stand?. <i>Gland Surgery</i> , 2020, 9, 1167-1169.	0.5	1

#	ARTICLE	IF	CITATIONS
177	De-escalation of neoadjuvant therapy for HER2-positive early breast cancer: an overview. <i>Annals of Palliative Medicine</i> , 2020, 9, 1352-1357.	0.5	0
178	Î±-Amidoamids as New Replacements of Antibioticsâ€”Research on the Chosen K12, R2â€”R4 E. coli Strains. <i>Materials</i> , 2020, 13, 5169.	1.3	19
179	Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature. <i>Cancers</i> , 2020, 12, 3317.	1.7	19
180	PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 575978.	1.3	7
181	Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version). <i>Translational Breast Cancer Research</i> , 0, 1, 27-27.	0.4	11
182	Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy. <i>Molecules</i> , 2020, 25, 5686.	1.7	19
183	The Cellular Prion Protein: A Promising Therapeutic Target for Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9208.	1.8	19
184	Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1134-1142.	0.8	4
185	Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. <i>BMC Cancer</i> , 2020, 20, 1091.	1.1	1
186	Trastuzumab emtansine: a game changer in HER2-positive early breast cancer. <i>Future Oncology</i> , 2020, 16, 2595-2609.	1.1	3
187	Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy. <i>Scientific Reports</i> , 2020, 10, 13078.	1.6	17
188	The Evolving Landscape of HER2-Directed Breast Cancer Therapy. <i>Current Treatment Options in Oncology</i> , 2020, 21, 82.	1.3	17
189	CSCO BC guideline: updates for HER2 positive breast cancer in 2020. <i>Translational Breast Cancer Research</i> , 0, 1, 4-4.	0.4	5
190	Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 901-910.	1.9	18
191	ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications. <i>Journal of Clinical Medicine</i> , 2020, 9, 2255.	1.0	12
192	Systemic Therapy of Common Tumours in Older Patients: Challenges and Opportunities. A Young International Society of Geriatric Oncology Review Paper. <i>Current Oncology Reports</i> , 2020, 22, 98.	1.8	3
193	The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer. <i>Cancers</i> , 2020, 12, 2081.	1.7	71
194	Sterilization Rate of the Axilla After Neoadjuvant Chemotherapy: The Scope for Conservative Surgery. <i>JCO Global Oncology</i> , 2020, 6, 1184-1191.	0.8	3

#	ARTICLE	IF	CITATIONS
195	Shortwave-infrared (SWIR) fluorescence molecular imaging using indocyanine green antibody conjugates for the optical diagnostics of cancerous tumours. <i>RSC Advances</i> , 2020, 10, 28171-28179.	1.7	14
196	Sentinel lymph node biopsy vs no axillary surgery in early breast cancer clinically and ultrasonographically node negative: A prospective randomized controlled trial VENU trial. <i>Breast Journal</i> , 2020, 26, 2087-2089.	0.4	3
197	Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer. <i>Npj Precision Oncology</i> , 2020, 4, 23.	2.3	1
198	Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1355.	3.4	119
199	Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 599-606.	1.1	11
200	Antibody drug conjugates in breast cancer: the chemotherapy of the future?. <i>Current Opinion in Oncology</i> , 2020, 32, 494-502.	1.1	25
201	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , The, 2020, 21, 1455-1464.	5.1	52
202	Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis. <i>Breast</i> , 2020, 54, 203-210.	0.9	8
203	Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer by combining magnetic resonance imaging and core needle biopsy. <i>Surgical Oncology</i> , 2020, 35, 447-452.	0.8	2
204	Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 903-913.	1.4	28
205	Leveraging Neoadjuvant Chemotherapy to Minimize the Burden of Axillary Surgery: a Review of Current Strategies and Surgical Techniques. <i>Current Breast Cancer Reports</i> , 2020, 12, 317-325.	0.5	0
206	A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy. <i>Medicine (United States)</i> , 2020, 99, e22886.	0.4	3
207	Management of brain metastases according to molecular subtypes. <i>Nature Reviews Neurology</i> , 2020, 16, 557-574.	4.9	104
208	<sc>HER2-positive</sc> breast cancer brain metastasis: A new and exciting landscape. <i>Cancer Reports</i> , 2022, 5, e1274.	0.6	54
209	Specific targeting of HER2-positive human breast carcinoma SK-BR-3 cells by amygdaline-ZHER2 affibody conjugate. <i>Molecular Biology Reports</i> , 2020, 47, 7139-7151.	1.0	6
210	Current advances in the diagnosis and personalized treatment of breast cancer: lessons from tumor biology. <i>Personalized Medicine</i> , 2020, 17, 399-420.	0.8	7
211	Survival analysis using a <sc>5-step</sc> stratified testing and amalgamation routine (5 STAR) in randomized clinical trials. <i>Statistics in Medicine</i> , 2020, 39, 4724-4744.	0.8	3
212	Are We RESPECTing Older Patients With Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2020, 38, 3727-3730.	0.8	0

#	ARTICLE	IF	CITATIONS
214	Evolving standards of care and new challenges in the management of HER2-positive breast cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 355-374.	157.7	77
215	Investigating the Association of the Biogenic Amine Profile in Urine with Therapeutic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. <i>Journal of Proteome Research</i> , 2020, 19, 4061-4070.	1.8	4
216	Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP). <i>Breast Cancer Research and Treatment</i> , 2020, 184, 481-489.	1.1	2
217	Antibody-Drug Conjugates: The Last Decade. <i>Pharmaceuticals</i> , 2020, 13, 245.	1.7	207
218	Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies. <i>ESMO Open</i> , 2020, 5, e000743.	2.0	7
219	Management of early breast cancer during the COVID-19 pandemic in Brazil. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 637-647.	1.1	20
220	Targeting molecular subtypes in solid cancers: successes and failures. <i>Current Opinion in Oncology</i> , 2020, 32, 488-493.	1.1	2
221	Intraoperative ultrasonography-guided surgery: An effective modality for breast conservation after neoadjuvant chemotherapy. <i>Breast Journal</i> , 2020, 26, 1680-1687.	0.4	2
222	Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer. <i>Breast Care</i> , 2020, 15, 608-618.	0.8	8
223	Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer: Rationale for the Prospective, Multicentric EUBREAST-01 Trial. <i>Cancers</i> , 2020, 12, 3698.	1.7	33
224	Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications. <i>Cells</i> , 2020, 9, 2644.	1.8	30
225	Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097008.	1.4	2
226	Impact of Breast Cancer Systemic Therapies on Fertility. <i>Current Breast Cancer Reports</i> , 2020, 12, 367-374.	0.5	2
227	Addressing Fertility: an Essential Aspect of Comprehensive Care for Young Patients with Breast Cancer. <i>Current Breast Cancer Reports</i> , 2020, 12, 381-390.	0.5	1
228	Enfortumab vedotin - next game-changer in urothelial cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 801-809.	1.4	17
229	Breast cancer in global health: beyond diversity and inequality. <i>International Journal of Surgery Global Health</i> , 2020, 3, e32-e32.	0.2	4
230	Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG). <i>Breast</i> , 2020, 54, 242-247.	0.9	14
231	Early HER2-Positive Breast Cancer: Current Treatment and Novel Approaches. <i>Breast Care</i> , 2020, 15, 560-569.	0.8	16

#	ARTICLE	IF	CITATIONS
232	Risk-based Approaches for Optimizing Treatment in HER2-Positive Early Stage Breast Cancer. <i>Seminars in Oncology</i> , 2020, 47, 249-258.	0.8	4
233	Reevaluating the role of antibody-drug conjugates in the treatment of patients with brain metastases. <i>Annals of Oncology</i> , 2020, 31, 1279-1281.	0.6	3
234	HER2DX: a tool that might inform treatment choices for HER2-positive breast cancer. <i>Lancet Oncology</i> , The, 2020, 21, 1392-1393.	5.1	1
235	Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer. <i>Scientific Reports</i> , 2020, 10, 18549.	1.6	7
236	Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 97-105.	1.1	36
239	Breast Cancer Outcomes of Neoadjuvant Versus Adjuvant Chemotherapy by Receptor Subtype: A Scoping Review. <i>Journal of Surgical Research</i> , 2020, 254, 83-90.	0.8	3
240	What's the Price? Toxicities of Targeted Therapies in Breast Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 55-70.	1.8	13
241	Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 5068-5077.	3.2	34
242	HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous blood-tumor barrier penetration unlinked to a passive marker. <i>Neuro-Oncology</i> , 2020, 22, 1625-1636.	0.6	23
243	Extent of Breast Surgery After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. <i>JAMA Surgery</i> , 2020, 155, 785.	2.2	0
244	Molecular and cellular mechanisms underlying brain metastasis of breast cancer. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 711-720.	2.7	82
245	Surgical Management of the Axilla in Elderly Women With Node-Positive Breast Cancer. <i>Journal of Surgical Research</i> , 2020, 254, 275-285.	0.8	7
246	The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy. <i>Communications Biology</i> , 2020, 3, 254.	2.0	11
247	Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. <i>Future Oncology</i> , 2020, 16, 899-909.	1.1	22
248	Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer. <i>Oncologist</i> , 2020, 25, 749-757.	1.9	28
249	Time trends of neoadjuvant chemotherapy for early breast cancer. <i>International Journal of Cancer</i> , 2020, 147, 3049-3058.	2.3	26
250	Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long-term outcomes for breast cancer patients. <i>Breast Journal</i> , 2020, 26, 1189-1198.	0.4	9
251	Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer. <i>Future Oncology</i> , 2020, 16, 1165-1177.	1.1	2

#	ARTICLE	IF	CITATIONS
252	Patterns of Failure in Women Who Have Residual Nodal Disease After Neoadjuvant Chemotherapy for Breast Cancer According to Extent of Lymph Node Surgery. <i>Clinical Breast Cancer</i> , 2020, 20, 431-438.	1.1	2
254	T-DM1-induced thrombocytopenia in breast cancer patients: New perspectives. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110407.	2.5	12
255	Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy. <i>Translational Oncology</i> , 2020, 13, 100794.	1.7	5
256	N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 613-622.	1.1	0
257	Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis. <i>PLoS ONE</i> , 2020, 15, e0234173.	1.1	4
258	CSCO breast cancer guideline: precise, economical and oriental. <i>Science China Life Sciences</i> , 2020, 63, 1410-1412.	2.3	12
259	Neoadjuvant treatment for HER2-positive breast cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 32-32.	0.4	44
260	The emerging role of antibody-drug conjugates in urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 551-561.	1.1	23
261	HER family in cancer progression: From discovery to 2020 and beyond. <i>Advances in Cancer Research</i> , 2020, 147, 109-160.	1.9	27
262	Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM). <i>Breast</i> , 2020, 53, 18-22.	0.9	7
263	Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 43-51.	1.1	18
264	Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond. <i>Npj Breast Cancer</i> , 2020, 6, 10.	2.3	106
265	Adjuvant and neoadjuvant therapy for breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 225-229.	0.6	96
266	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , 2020, 21, 519-530.	5.1	441
267	Cancer prevention and treatment using combination therapy with natural compounds. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 265-285.	1.3	92
268	Update Breast Cancer 2020 Part 1 "Early Breast Cancer: Consolidation of Knowledge About Known Therapies. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 277-287.	0.8	16
269	Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 27-27.	0.4	37
270	Advances in Antibody-Drug Conjugate Design: Current Clinical Landscape and Future Innovations. <i>SLAS Discovery</i> , 2020, 25, 843-868.	1.4	47

#	ARTICLE	IF	CITATIONS
271	Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. <i>European Journal of Cancer</i> , 2020, 130, 92-101.	1.3	26
272	Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. <i>Medical Sciences (Basel, Switzerland)</i> , 2020, 8, 18.	1.3	72
273	4. Supportivtherapie. , 2020, , 127-216.		0
274	The Diagnostic Performance of Minimally Invasive Biopsy in Predicting Breast Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 933.	1.3	10
275	Progress in Local Treatment of Breast Cancer: A Narrative Review. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2020, 42, 356-364.	0.3	5
276	Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach. <i>JCO Oncology Practice</i> , 2020, 16, 665-674.	1.4	44
277	Impact of progesterone receptor status on response to neoadjuvant chemotherapy in estrogen receptor- positive breast cancer patients. <i>Journal of Surgical Oncology</i> , 2020, 122, 861-868.	0.8	2
278	Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic. <i>New England Journal of Medicine</i> , 2020, 383, 262-272.	13.9	12
279	Local management after neoadjuvant treatment for breast cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 34-34.	0.4	4
280	SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. <i>Future Oncology</i> , 2020, 16, 1801-1813.	1.1	8
281	Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy. <i>PLoS ONE</i> , 2020, 15, e0234191.	1.1	51
282	The Landmark Series: Neoadjuvant Endocrine Therapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 3393-3401.	0.7	14
284	Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492093181.	0.6	7
285	Sarcopenia and monocyte-to-lymphocyte ratio as prognostic factors in early-stage breast cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 737-737.	0.7	1
286	Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100188.	0.7	13
287	Anti-HER2 therapy for breast cancer in older patients. <i>Future Oncology</i> , 2020, 16, 1393-1407.	1.1	0
288	Advances in Care of the Breast Cancer Patient. <i>Seminars in Oncology</i> , 2020, 47, 176.	0.8	0
290	Characterization of T-DM1-resistant breast cancer cells. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00617.	1.1	9

#	ARTICLE	IF	CITATIONS
291	Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 321-332.	1.1	6
292	MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive and/or Hormone Receptorâ€“Negative Breast Cancers in the I-SPY 2 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1059-1069.	0.8	69
293	BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study. <i>Diagnostics</i> , 2020, 10, 119.	1.3	6
294	Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 597-609.	1.1	24
295	What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?. <i>Clinical Cancer Research</i> , 2020, 26, 2783-2788.	3.2	27
296	Role of Axillary Surgery After Neoadjuvant Chemotherapy. <i>JCO Global Oncology</i> , 2020, 6, 238-241.	0.8	15
297	Landscape of combination therapy trials in breast cancer brain metastasis. <i>International Journal of Cancer</i> , 2020, 147, 1939-1952.	2.3	31
298	Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 334-343.	0.4	81
299	Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond. <i>Trends in Cancer</i> , 2020, 6, 130-146.	3.8	58
300	Incidence and Survival by Human Epidermal Growth Factor Receptor 2 Status in Young Women With Stage I-III Breast Cancer: SEER, 2010-2016. <i>Clinical Breast Cancer</i> , 2020, 20, e410-e422.	1.1	8
301	Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 647-655.	1.1	5
302	Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine. <i>Clinical Cancer Research</i> , 2020, 26, 1045-1053.	3.2	13
303	Adding pertuzumab to adjuvant therapy for high-risk HER2-positive early breast cancer in APHINITY: a GRADE analysis. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 423-430.	0.6	3
304	Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01. <i>Breast Cancer</i> , 2020, 27, 631-641.	1.3	6
305	A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxelâ€“carboplatinâ€“trastuzumabâ€“pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 135-146.	1.1	26
306	Glioblastoma precision therapy: From the bench to the clinic. <i>Cancer Letters</i> , 2020, 475, 79-91.	3.2	27
307	Prospective study of the relevance of circulating tumor cell status and neoadjuvant chemotherapy effectiveness in early breast cancer. <i>Cancer Medicine</i> , 2020, 9, 2290-2298.	1.3	8
308	Designing Chimeric Molecules for Drug Discovery by Leveraging Chemical Biology. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 1908-1928.	2.9	32

#	ARTICLE	IF	CITATIONS
309	Neoadjuvant nab-paclitaxel in breast cancer: who stands to benefit?. <i>Chinese Clinical Oncology</i> , 2020, 9, 42-42.	0.4	0
310	Neoadjuvant therapy and sentinel lymph node biopsy in HER2-positive breast cancer patients: results from the PEONY trial. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 423-428.	1.1	8
311	Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1222-1230.	3.0	23
312	Trastuzumab: Weighing the Benefits and the Risks. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1181-1182.	3.0	2
313	Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: a systematic review and meta-analysis. <i>Therapeutic Advances in Drug Safety</i> , 2020, 11, 204209862091505.	1.0	9
314	Application of trastuzumab emtansine in HER2-positive and KRAS/BRAF-mutated colon cancer cells. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13255.	1.7	5
315	First Reported Use of Radiofrequency Identification (RFID) Technique for Targeted Excision of Suspicious Axillary Lymph Nodes in Early Stage Breast Cancer – Evaluation of Feasibility and Review of Current Recommendations. <i>In Vivo</i> , 2020, 34, 1207-1213.	0.6	18
317	Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB). <i>Breast Cancer Research and Treatment</i> , 2020, 181, 249-254.	1.1	19
319	ESMO – ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). <i>Annals of Oncology</i> , 2020, 31, 674-696.	0.6	172
320	What are the appropriate thresholds for High Quality Performance Indicators for breast surgery in Australia and New Zealand?. <i>Breast</i> , 2020, 51, 94-101.	0.9	4
321	Neoadjuvant or adjuvant chemotherapy in early breast cancer?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1071-1082.	0.9	62
322	Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials. <i>ESMO Open</i> , 2020, 5, e000659.	2.0	6
323	Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy. <i>Frontiers in Pharmacology</i> , 2020, 11, 445.	1.6	30
324	HER2-Low Breast Cancer: Pathological and Clinical Landscape. <i>Journal of Clinical Oncology</i> , 2020, 38, 1951-1962.	0.8	353
325	Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 487-497.	1.1	272
326	Tailoring neoadjuvant chemotherapy for patients with breast cancer who have achieved pathologic complete response. <i>Translational Cancer Research</i> , 2020, 9, 1205-1214.	0.4	1
327	Neoadjuvant endocrine therapy for estrogen receptor-positive primary breast cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 30-30.	0.4	2
328	Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session. <i>Journal of Controlled Release</i> , 2020, 323, 269-281.	4.8	49

#	ARTICLE	IF	CITATIONS
329	Application of magnetic nanoparticles in nucleic acid detection. <i>Journal of Nanobiotechnology</i> , 2020, 18, 62.	4.2	157
330	Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer. <i>Cancer</i> , 2020, 126, 3132-3139.	2.0	14
331	Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology. <i>BioDrugs</i> , 2020, 34, 435-462.	2.2	24
332	Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e159-e170.	1.8	7
333	Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e1-e16.	1.8	9
334	Optimizing Anti-HER2 Therapy in early breast cancer: updates from the KRISTINE trial. <i>Annals of Palliative Medicine</i> , 2020, 9, 504-509.	0.5	2
335	Optimal Tumor Reduction Rate and Modalities for Predicting pCR in Women With Breast Cancer. <i>Anticancer Research</i> , 2020, 40, 2303-2309.	0.5	2
336	FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4180-4185.	3.2	41
337	HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers. <i>Cancer Discovery</i> , 2020, 10, 674-687.	7.7	149
338	Escalating and De-escalating Therapy for Early-Stage HER2-Positive Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 3-13.	1.8	8
339	Antibody-Drug Conjugates: Patient and Treatment Selection. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 105-114.	1.8	12
340	Real-World Outcomes Among Older Mexican Women with Breast Cancer Treated with Neoadjuvant Chemotherapy. <i>Oncologist</i> , 2020, 25, 1023-1031.	1.9	1
341	Moving trastuzumab emtansine (T-DM1) to the early setting of breast cancer treatment. <i>Annals of Palliative Medicine</i> , 2020, 9, 512-516.	0.5	3
342	TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer. <i>Future Oncology</i> , 2020, 16, 705-715.	1.1	62
343	Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. <i>Seminars in Cancer Biology</i> , 2021, 72, 123-135.	4.3	162
344	Prognostic and predictive parameters in breast pathology: a pathologist's primer. <i>Modern Pathology</i> , 2021, 34, 94-106.	2.9	14
345	Tumor-infiltrating lymphocytes benefit prediction of axillary pathologic response and prognostication of event-free survival in HER2-positive and biopsy-proven node-positive breast cancer treated with neoadjuvant therapy. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 629-638.	1.1	2
346	Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients sequentially, or better simultaneously?. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1-7.	1.0	8

#	ARTICLE	IF	CITATIONS
347	Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition. <i>Journal of Nuclear Medicine</i> , 2021, 62, 366-371.	2.8	4
348	Effect of level of hormone-receptor expression on treatment outcomes of triple-positive early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 459-467.	1.1	6
349	Update on systemic treatment for newly diagnosed inflammatory breast cancer. <i>Journal of Advanced Research</i> , 2021, 29, 1-12.	4.4	20
351	Oncoplastic Breast-Conserving Surgery: Can We Reduce Rates of Mastectomy and Chemotherapy Use in Patients with Traditional Indications for Mastectomy?. <i>Annals of Surgical Oncology</i> , 2021, 28, 2199-2209.	0.7	8
352	The Prognostic Value of Axillary Staging Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2182-2190.	0.7	9
353	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 685-693.	0.8	66
354	A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 807-815.	1.1	2
355	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. <i>Clinical Breast Cancer</i> , 2021, 21, 80-91.e7.	1.1	140
356	Predictive value of tumor-infiltrating lymphocytes for response to neoadjuvant chemotherapy and breast cancer prognosis. <i>Journal of Surgical Oncology</i> , 2021, 123, 89-95.	0.8	9
357	Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188487.	3.3	16
358	Special Review: The future of Immunotherapy. <i>Immunotherapy Advances</i> , 2021, 1, .	1.2	5
359	Updates on the treatment of invasive breast cancer: Quo Vadimus?. <i>Maturitas</i> , 2021, 145, 64-72.	1.0	7
360	Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 241-250.	1.1	6
361	Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy. <i>European Journal of Cancer</i> , 2021, 143, 134-146.	1.3	44
362	Treatment strategies for breast cancer brain metastases. <i>British Journal of Cancer</i> , 2021, 124, 142-155.	2.9	117
363	Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. <i>Annals of Oncology</i> , 2021, 32, 229-239.	0.6	201
364	Concurrent Radiation and Modern Systemic Therapies for Breast Cancer: An Ever-Expanding Frontier. <i>Clinical Breast Cancer</i> , 2021, 21, 120-127.	1.1	2
365	Experimental HER2- targeted therapies for biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 389-399.	1.9	9

#	ARTICLE	IF	CITATIONS
366	Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 3243-3253.	0.7	48
367	Primary Trastuzumab Resistance After (Neo)adjuvant Trastuzumab-containing Treatment for Patients With HER2-positive Breast Cancer in Real-world Practice. <i>Clinical Breast Cancer</i> , 2021, 21, 191-198.	1.1	2
368	Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. <i>European Journal of Surgical Oncology</i> , 2021, 47, 804-812.	0.5	91
369	Machine learning to predict the cancer-specific mortality of patients with primary non-metastatic invasive breast cancer. <i>Surgery Today</i> , 2021, 51, 756-763.	0.7	16
370	Can We Reliably Identify the Pathological Outcomes of Neoadjuvant Chemotherapy in Patients with Breast Cancer? Development and Validation of a Logistic Regression Nomogram Based on Preoperative Factors. <i>Annals of Surgical Oncology</i> , 2021, 28, 2632-2645.	0.7	22
371	Does Failure to Achieve Pathologic Complete Response with Neoadjuvant Chemotherapy Identify Node-Negative Patients Who Would Benefit from Postmastectomy Radiation or Regional Nodal Irradiation?. <i>Annals of Surgical Oncology</i> , 2021, 28, 1328-1335.	0.7	2
372	Molecular Biology in the Breast Clinics—Current status and future perspectives. <i>Indian Journal of Surgical Oncology</i> , 2021, 12, 7-20.	0.3	0
373	Research advances and new challenges in overcoming triple-negative breast cancer. , 2021, 4, 517-542.		11
374	Systemic Therapy for the Treatment of Breast Cancer. , 2021, , 81-87.		0
375	Paraneoplastic Encephalitis Associated with Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Breast Cancer</i> , 2021, 24, 106.	0.8	2
376	The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making. <i>BMC Cancer</i> , 2021, 21, 90.	1.1	11
377	Prolonged Survival in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressed Metastatic Breast Cancer after Targeted Therapy is Dominantly Contributed by Luminal-Human Epidermal Growth Factor Receptor-2 Population. <i>Oncologie</i> , 2021, 23, 229-239.	0.2	1
378	Ado-trastuzumab emtansine: Avoiding side-effects of traditional HER2 positive breast cancer treatment. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1770-1774.	0.5	0
379	Recent advances in neoadjuvant therapy for breast cancer. <i>Faculty Reviews</i> , 2021, 10, 2.	1.7	8
380	Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 779.	1.8	53
381	Liquid biopsy enters the clinic — implementation issues and future challenges. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 297-312.	12.5	609
382	Axillary Primary and Breast Cancer Management. <i>Current Breast Cancer Reports</i> , 2021, 13, 42-48.	0.5	0
383	A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 557-566.	1.1	19

#	ARTICLE	IF	CITATIONS
384	Impact of immunohistochemical profile changes following neoadjuvant therapy in the treatment of breast cancer. <i>Ecancermedicalsecience</i> , 2021, 15, 1162.	0.6	1
385	Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110069.	1.4	10
386	Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab. <i>Journal of Breast Cancer</i> , 2021, 24, 359.	0.8	4
387	Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. <i>Lancet Oncology</i> , The, 2021, 22, e18-e28.	5.1	49
388	Planning Adjuvant Treatment. , 2021, , 569-577.		0
389	Management of early-stage breast cancer patients during the coronavirus disease 2019 (COVID-19) pandemic: The experience in China from a surgical standpoint. <i>Journal of Cancer</i> , 2021, 12, 2190-2198.	1.2	2
390	Mechanisms contributing to ado-trastuzumab emtansine-induced toxicities: a gateway to better understanding of ADC-associated toxicities. <i>Antibody Therapeutics</i> , 2021, 4, 55-59.	1.2	8
391	Neo-Bioscore in Guiding Post-surgical Therapy in Patients With Triple-negative Breast Cancer Who Received Neoadjuvant Chemotherapy. <i>In Vivo</i> , 2021, 35, 1041-1049.	0.6	4
392	The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2111-2119.	0.7	45
393	Adjuvant therapy in older patients with breast cancer. <i>Annals of Breast Surgery</i> , 0, 6, 15-15.	0.8	0
394	Key studies that have changed the history and treatment of early HER2+ breast cancer: focus on individual therapy. <i>Opuholi Zenskoj Reproktivnoj Sistemy</i> , 2021, 16, 46-56.	0.1	3
395	HER2-Positive (HER2 +) Breast Cancer. , 2021, , .		0
396	HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens. <i>Cancers</i> , 2021, 13, 370.	1.7	2
397	Adaptation of international coronavirus disease 2019 and breast cancer guidelines to local context. <i>World Journal of Clinical Oncology</i> , 2021, 12, 31-42.	0.9	3
398	Sentinel lymph node biopsy using single-agent mapping tracer (blue dye) after neoadjuvant chemotherapy in a Brazilian cohort of breast cancer patients. Real world evidence. <i>Acta Cirurgica Brasileira</i> , 2021, 36, e360608.	0.3	2
399	Identification of Prostaglandin F2 Receptor Negative Regulator (PTGFRN) as an internalizable target in cancer cells for antibody-drug conjugate development. <i>PLoS ONE</i> , 2021, 16, e0246197.	1.1	5
400	Antibody-“drug conjugates in solid tumors: a look into novel targets. <i>Journal of Hematology and Oncology</i> , 2021, 14, 20.	6.9	129
401	Anthracycline-containing <i>versus</i> carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110090.	1.4	11

#	ARTICLE	IF	CITATIONS
402	The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer Subtypes. <i>Cancers</i> , 2021, 13, 171.	1.7	6
403	The Development of Antibody-Drug Conjugates for Urothelial Carcinoma Treatment. <i>The Korean Journal of Urological Oncology</i> , 2021, 19, 30-39.	0.1	0
404	Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities. <i>Seminars in Cancer Biology</i> , 2022, 78, 78-89.	4.3	16
405	Clinical Perspectives in Addressing Unsolved Issues in (Neo)Adjuvant Therapy for Primary Breast Cancer. <i>Cancers</i> , 2021, 13, 926.	1.7	5
406	PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy. <i>Cancers</i> , 2021, 13, 746.	1.7	9
407	Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2). <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1235-1244.	0.5	6
408	Monoclonal antibody-based cancer therapies. <i>Chinese Journal of Chemical Engineering</i> , 2021, 30, 301-307.	1.7	7
409	Extracellular vesicles as modifiers of antibody-drug conjugate efficacy. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12070.	5.5	17
410	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 3116-3125.	3.2	9
411	Unlocking the potential of antibody-drug conjugates for cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 327-344.	12.5	498
412	Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 151-159.	1.0	10
413	Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy on pathologic complete response rate in HER2-negative breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 167-176.	1.1	1
414	A multistage oral delivery system of PTX for improving oral bioavailability and enhancing anticancer efficacy. <i>Drug Development and Industrial Pharmacy</i> , 2021, 47, 259-267.	0.9	3
415	Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study. <i>Cancer Communications</i> , 2021, 41, 171-182.	3.7	15
416	Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	36
417	Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art. <i>Cancers</i> , 2021, 13, 902.	1.7	6
419	Better overall survival in patients who achieve pathological complete response after neoadjuvant chemotherapy for breast cancer in a Chilean public hospital. <i>Ecancermedicalscience</i> , 2021, 15, 1185.	0.6	3
420	Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e575-e583.	1.1	7

#	ARTICLE	IF	CITATIONS
421	Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 883-891.	1.1	1
422	Cardiac surveillance for anti-HER2 chemotherapy. <i>Cleveland Clinic Journal of Medicine</i> , 2021, 88, 110-116.	0.6	7
423	Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments. <i>European Journal of Cancer</i> , 2021, 144, 310-316.	1.3	34
424	Novel Anti-FOLR1 Antibody-Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells. <i>Antibodies</i> , 2021, 10, 6.	1.2	10
425	Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis. <i>Npj Breast Cancer</i> , 2021, 7, 17.	2.3	2
426	Impact of Pathologic Complete Response following Neoadjuvant Chemotherapy±Trastuzumab in Locally Advanced Breast Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-10.	0.6	2
427	Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 753-760.	1.1	3
428	Clinical Development of New Antibody-Drug Conjugates in Breast Cancer: To Infinity and Beyond. <i>BioDrugs</i> , 2021, 35, 159-174.	2.2	30
430	Clinical application of circulating tumor DNA in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1431-1442.	1.2	5
431	Reconsidering the Meaning of Curing Primary Breast Cancer as a Systemic Disease. <i>Frontiers in Oncology</i> , 2021, 11, 639420.	1.3	0
432	Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 199-211.	1.0	15
433	Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy. <i>Npj Breast Cancer</i> , 2021, 7, 26.	2.3	7
434	Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer. <i>Cell Death and Disease</i> , 2021, 12, 288.	2.7	11
435	Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, . .	0.5	1
436	Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases. <i>BMC Cancer</i> , 2021, 21, 223.	1.1	19
437	Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 467-470.	3.0	13
438	Validation and comparison of Breast Graded Prognostic Assessment scores in patients with breast cancer and brain metastases. <i>Clinical and Translational Oncology</i> , 2021, 23, 1761-1768.	1.2	3
439	Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy. <i>Cells</i> , 2021, 10, 670.	1.8	20

#	ARTICLE	IF	CITATIONS
440	Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2. <i>Scientific Reports</i> , 2021, 11, 6993.	1.6	4
441	Integrating Adjuvant Radiation with Post-Neoadjuvant Therapies in Early Breast Cancer. <i>Current Oncology Reports</i> , 2021, 23, 58.	1.8	1
442	Value of ultrafast and standard dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the presence and extension of residual disease after neoadjuvant chemotherapy in breast cancer. <i>Japanese Journal of Radiology</i> , 2021, 39, 791-801.	1.0	12
443	RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 42.	2.2	11
444	Clinical impact of the biology of synchronous axillary lymph node metastases in primary breast cancer on preoperative treatment strategy. <i>Journal of Surgical Oncology</i> , 2021, 123, 1513-1520.	0.8	3
445	Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic. <i>Current Oncology</i> , 2021, 28, 1338-1347.	0.9	10
446	Breast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives. <i>Cancers</i> , 2021, 13, 1078.	1.7	41
447	Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103280.	2.0	22
448	Cardiovascular toxicity of breast cancer treatment: an update. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 15-24.	1.1	7
449	HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models. <i>Cancers</i> , 2021, 13, 2007.	1.7	11
450	Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer. <i>ESMO Open</i> , 2021, 6, 100063.	2.0	7
451	Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer. <i>Seminars in Cancer Biology</i> , 2021, 77, 42-55.	4.3	10
453	Personalized and targeted therapies. <i>ChemistrySelect</i> , 2023, 8, 2103-2126.	0.7	0
454	Axillary Pathologic Complete Response After Neoadjuvant Systemic Therapy by Breast Cancer Subtype in Patients With Initially Clinically Node-Positive Disease. <i>JAMA Surgery</i> , 2021, 156, e210891.	2.2	75
455	In vitro effects of Trastuzumab Emtansine (T-DM1) and concurrent irradiation on HER2-positive breast cancer cells. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2021, 25, 126-134.	0.6	10
456	Locally Advanced Breast Cancer—A Narrative Review of Management in the Indian Scenario. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021, 42, 137-145.	0.1	0
457	Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer. <i>ESMO Open</i> , 2021, 6, 100076.	2.0	6
458	T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study. <i>ESMO Open</i> , 2021, 6, 100099.	2.0	12

#	ARTICLE	IF	CITATIONS
459	Palpable Adenopathy Does Not Indicate High-Volume Axillary Nodal Disease in Hormone Receptor-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 6060-6068.	0.7	9
460	Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). <i>Annals of Surgical Oncology</i> , 2021, 28, 5960-5971.	0.7	22
461	Prognostic factors for patients with metastatic breast cancer: a literature review. <i>Translational Cancer Research</i> , 2021, 10, 1644-1655.	0.4	0
462	Neoadjuvant radiotherapy for locally advanced and high-risk breast cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, 65, 345-353.	0.9	11
463	The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer. <i>ESMO Open</i> , 2021, 6, 100074.	2.0	7
464	Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4687.	1.8	23
465	Update Breast Cancer 2020 Part 5 "Moving Therapies From Advanced to Early Breast Cancer Patients. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 469-480.	0.8	6
466	Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study). <i>Breast Cancer</i> , 2021, 28, 1023-1037.	1.3	5
467	Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 759-768.	1.1	4
468	New Treatment Strategies for the Inflammatory Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 50.	1.3	10
470	Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework. <i>British Journal of Cancer</i> , 2021, 125, 155-163.	2.9	27
471	Neoadjuvant and adjuvant end-points in health technology assessment in oncology. <i>European Journal of Cancer</i> , 2021, 147, 40-50.	1.3	6
472	Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?. <i>Cancers</i> , 2021, 13, 1655.	1.7	6
473	Is Residual Nodal Disease at Axillary Dissection Associated with Tumor Subtype in Patients with Low Volume Sentinel Node Metastasis After Neoadjuvant Chemotherapy?. <i>Annals of Surgical Oncology</i> , 2021, 28, 6044-6050.	0.7	14
474	Harnessing the Physiological Functions of Cellular Prion Protein in the Kidneys: Applications for Treating Renal Diseases. <i>Biomolecules</i> , 2021, 11, 784.	1.8	4
475	Predictive value of 18F-FDG PET/CT indices on extensive residual cancer burden in breast cancer patients treated with neoadjuvant chemotherapy. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2022, 41, 171-178.	0.1	1
476	Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity. <i>Cancers</i> , 2021, 13, 2492.	1.7	5
477	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. <i>Journal of Clinical Oncology</i> , 2021, 39, 1448-1457.	0.8	171

#	ARTICLE	IF	CITATIONS
478	Impact of timing of adjuvant chemotherapy for early breast cancer: the Royal Marsden Hospital experience. <i>British Journal of Cancer</i> , 2021, 125, 299-304.	2.9	2
479	How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer. <i>Oncology and Therapy</i> , 2021, 9, 297-309.	1.0	2
480	Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience. <i>Journal of Oncology</i> , 2021, 2021, 1-7.	0.6	10
481	New horizons in imaging and surgical assessment of breast cancer lymph node metastasis. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 311-322.	1.1	8
482	Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 2042-2053.	0.6	37
483	Risk Minimization of Antibody-Drug Conjugates in Oncology: A Review. <i>Drug Safety</i> , 2021, 44, 733-742.	1.4	6
484	Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 341-351.	1.0	3
486	Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy using Biomarkers, Ultrasound, and Diffuse Optical Tomography. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 615-630.	1.1	8
487	Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 1485-1505.	0.8	395
488	Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. <i>Cancer Discovery</i> , 2021, 11, 2474-2487.	7.7	92
489	Breast cancer. <i>Lancet, The</i> , 2021, 397, 1750-1769.	6.3	731
490	Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (â€œMETRICâ€): a randomized multicenter study. <i>Npj Breast Cancer</i> , 2021, 7, 57.	2.3	26
491	Current Treatment Approaches for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Adjuvant and Neoadjuvant Settings. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, 42, .	0.1	1
492	Neoadjuvant Chemotherapy for Breast Cancer: Moving Beyond Pathological Complete Response in the Molecular Age. <i>Acta Medica Academica</i> , 2021, 50, 88.	0.3	8
493	Systemic toxicities of trastuzumab-emtansine predict tumor response in <sc>HER2</sc>+ metastatic breast cancer. <i>International Journal of Cancer</i> , 2021, 149, 909-916.	2.3	5
494	Impact of Breast Cancer Pretreatment Nodal Burden and Disease Subtype on Axillary Surgical Management. <i>Journal of Surgical Research</i> , 2021, 261, 67-73.	0.8	2
495	Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 7347-7355.	0.7	6
496	Highlights of the 17th St. Gallen International Breast Cancer Conference 2021: customising local and systemic therapies. <i>Ecancermedalscience</i> , 2021, 15, 1236.	0.6	8

#	ARTICLE	IF	CITATIONS
497	Is pathological complete response predictable after neoadjuvant chemotherapy in breast cancer? A single institution's retrospective experience. ANZ Journal of Surgery, 2021, 91, 1779-1783.	0.3	1
498	Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus. Geburtshilfe Und Frauenheilkunde, 2021, 81, 637-653.	0.8	5
499	Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib. Breast Cancer: Targets and Therapy, 2021, Volume 13, 361-381.	1.0	8
500	The Clinical Relevance of Target Lymph Node Biopsy after Primary Systemic Therapy in Initially Node-Positive Breast Cancer Patients. Cancers, 2021, 13, 2620.	1.7	2
501	Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis. Frontiers in Oncology, 2021, 11, 608781.	1.3	5
502	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancerâ€”The Penelope-B Trial. Journal of Clinical Oncology, 2021, 39, 1518-1530.	0.8	153
503	Targeted Therapies in Older Adults With Solid Tumors. Journal of Clinical Oncology, 2021, 39, 2128-2137.	0.8	7
504	Relative Risk of Peripheral Neuropathy With Ado-Trastuzumab Emtansine (T-DM1) Compared to Taxane-Based Regimens in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Cancers: A Systematic Review and Meta-Analysis. Cureus, 2021, 13, e15282.	0.2	4
505	Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in the United States. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 340-349.	0.6	9
506	Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study. Clinical Breast Cancer, 2021, 21, 539-551.	1.1	13
507	Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study. Breast Cancer Research and Treatment, 2021, 189, 93-101.	1.1	1
508	Sentinel lymph node assessment in breast cancerâ€”an update on current recommendations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 95-107.	1.4	16
510	Breast Cancer in Adolescent and Young Adult Women Under the Age of 40 Years. JCO Oncology Practice, 2021, 17, 305-313.	1.4	62
511	Time to Completion of Breast Cancer Treatment and Survival. Annals of Surgical Oncology, 2021, 28, 8600-8608.	0.7	6
512	De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer. Current Breast Cancer Reports, 2021, 13, 151-156.	0.5	1
513	Antibodyâ€”Drug Conjugates for the Treatment of Breast Cancer. Cancers, 2021, 13, 2898.	1.7	34
514	Expression pattern and prognostic impact of glycoprotein non-metastatic B (GPNMB) in triple-negative breast cancer. Scientific Reports, 2021, 11, 12171.	1.6	15
515	Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Research and Treatment, 2021, 188, 21-36.	1.1	62

#	ARTICLE	IF	CITATIONS
516	Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis. <i>Clinical Breast Cancer</i> , 2022, 22, e21-e29.	1.1	8
517	Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. <i>Oncologist</i> , 2021, 26, e1327-e1338.	1.9	31
518	The past, present, and future of breast cancer models for nanomedicine development. <i>Advanced Drug Delivery Reviews</i> , 2021, 173, 306-330.	6.6	65
519	Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessmentâ€“driven analyses from the ExteNET study. <i>European Journal of Cancer</i> , 2021, 150, 268-277.	1.3	3
521	The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively. <i>Cancer Medicine</i> , 2021, 10, 4677-4696.	1.3	25
522	Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies. <i>Cancers</i> , 2021, 13, 2927.	1.7	54
523	Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab. <i>Npj Breast Cancer</i> , 2021, 7, 75.	2.3	5
524	Finding the Sweet Spot in the Management of Early HER2+ Breast Cancer. <i>JCO Oncology Practice</i> , 2021, 17, 331-333.	1.4	1
525	Targeting HER2 genomic alterations in non-small cell lung cancer. <i>Journal of the National Cancer Center</i> , 2021, 1, 58-73.	3.0	13
526	Locally Advanced Breast Cancer: Treatment Patterns and Predictors of Survival in a Saudi Tertiary Center. <i>Cureus</i> , 2021, 13, e15526.	0.2	0
527	Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 686591.	1.3	0
528	Update Breast Cancer 2021 Part 3 â€“ Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 654-665.	0.8	4
529	Mastering the Use of Novel Anti-HER2 Treatment Options. <i>JCO Oncology Practice</i> , 2021, 17, 605-606.	1.4	6
530	When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e79-e89.	1.8	3
531	Investigational antibody-drug conjugates in clinical trials for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1-7.	1.9	3
532	Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 393-407.	1.0	14
533	Progress in Gynecologic Cancers with Antibody Drug Conjugates. <i>Current Oncology Reports</i> , 2021, 23, 89.	1.8	3
534	Management of Early-Stage Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. <i>JCO Oncology Practice</i> , 2021, 17, 320-330.	1.4	14

#	ARTICLE	IF	CITATIONS
536	Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 945-962.	1.4	26
537	Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 167-175.	1.1	10
538	Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. <i>Oncologist</i> , 2021, 26, 827-834.	1.9	28
539	A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, 1-9.	1.1	6
540	Systemic therapy for early breast cancer in older adults. <i>Current Opinion in Oncology</i> , 2021, Publish Ahead of Print, 574-583.	1.1	1
541	First-Line Efficacy of Anti-HER2 Treatments in Previously Treated HER2-Positive Metastatic Breast Cancer Patients: A Retrospective Observational Study Investigating the Efficacy of Re-Exposure to Anti-HER2 Therapy for HER2-Positive Metastatic Breast Cancer Patients in Comparison with Naïve Patients. <i>Breast Care</i> , 0, 1-7.	0.8	0
542	Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 592393.	1.3	1
543	Managing the Minefields in Optimal Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 943-944.	0.4	0
544	Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 2+ Invasive Breast Cancer. <i>Anticancer Research</i> , 2021, 41, 4143-4149.	0.5	1
545	Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 978.	3.4	65
546	Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). <i>Lancet Oncology</i> , The, 2021, 22, e327-e340.	5.1	121
547	MicroRNA-301a promotes triple-negative breast cancer progression through downregulating MEOX2. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 945.	0.8	5
548	Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 5477-5485.	0.7	3
549	Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 98, 102222.	3.4	21
550	Central neurotoxicity induced by trastuzumab emtansine (T-DM1). <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, 1146-1149.	0.7	5
551	Assessment of racial differences in the incidence of thrombocytopenia induced by trastuzumab emtansine: a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2021, 9, 1139-1139.	0.7	4
552	Corneal nerve changes following treatment with neurotoxic anticancer drugs. <i>Ocular Surface</i> , 2021, 21, 221-237.	2.2	7
553	Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. <i>Current Treatment Options in Oncology</i> , 2021, 22, 79.	1.3	13

#	ARTICLE	IF	CITATIONS
554	Shortwave-Infrared Fluorescent Molecular Imaging Probes Based on ICG-Conjugation Extended Indocyanine Green. <i>Bioconjugate Chemistry</i> , 2021, 32, 1541-1547.	1.8	22
555	Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting. <i>Cells</i> , 2021, 10, 1685.	1.8	15
556	Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma. <i>Cancers</i> , 2021, 13, 3540.	1.7	50
557	Optimizing HER2-positive breast cancer therapy through neoadjuvant platforms: controversies and concepts. <i>Translational Breast Cancer Research</i> , 0, 2, 19-19.	0.4	0
558	Tatibody, a recombinant antibody with higher internalization potency. <i>Molecular Immunology</i> , 2021, 135, 320-328.	1.0	0
559	Precision medicine in breast cancer: From clinical trials to clinical practice. <i>Cancer Treatment Reviews</i> , 2021, 98, 102223.	3.4	34
560	Neoadjuvant chemotherapy choices from population selection to regimen design: the St. Gallen International Expert Consensus Conference 2021. <i>Translational Breast Cancer Research</i> , 0, 2, 25-25.	0.4	0
561	Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World. <i>Frontiers in Oncology</i> , 2021, 11, 704842.	1.3	0
562	Predictive Value of Pretreatment Peripheral Neutrophil-to-Lymphocyte Ratio for Response to Neoadjuvant Chemotherapy and Breast Cancer Prognosis. <i>Cancer Management and Research</i> , 2021, Volume 13, 5889-5898.	0.9	6
563	Determining the Optimal Treatment of Locally Advanced Breast Cancer With Sequelae of Dermatomyositis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 940-941.	0.4	1
564	Site-Specific Antibody Conjugation to Engineered Double Cysteine Residues. <i>Pharmaceuticals</i> , 2021, 14, 672.	1.7	10
565	Does preoperative MRI accurately stratify early-stage HER2+ breast cancer patients to upfront surgery vs neoadjuvant chemotherapy?. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 307-315.	1.1	3
566	MINimal vs. MAXimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer: Protocol of a Dutch Multicenter Registry Study (MINIMAX). <i>Clinical Breast Cancer</i> , 2022, 22, e59-e64.	1.1	21
567	Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 632357.	1.3	14
568	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2375-2385.	0.8	76
569	Controversies in Breast Cancer Surgery. <i>Surgical Clinics of North America</i> , 2021, 101, 1033-1044.	0.5	4
570	Utility of the CPS+ÂEG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. <i>European Journal of Cancer</i> , 2021, 153, 203-212.	1.3	8
571	Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. <i>Journal of Clinical Oncology</i> , 2021, 39, 2720-2731.	0.8	52

#	ARTICLE	IF	CITATIONS
572	Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. <i>Breast Cancer Research</i> , 2021, 23, 84.	2.2	108
573	Circulating tumor cells as prognostic biomarkers in breast cancer: current status and future prospects. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1037-1048.	1.5	7
574	Loss of HER2-positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes. <i>Journal of Surgical Oncology</i> , 2021, 124, 1224-1234.	0.8	9
575	Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape. <i>ESMO Open</i> , 2021, 6, 100204.	2.0	30
577	Lost clips after targeted lymph node biopsy in breast cancer patients: Follow-up of the CLIP-study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1907-1912.	0.5	5
578	Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?. <i>Clinical Drug Investigation</i> , 2021, 41, 757-773.	1.1	1
579	Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study). <i>Cancers</i> , 2021, 13, 4008.	1.7	3
580	Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?. <i>Journal of Clinical Oncology</i> , 2021, 39, 3541-3545.	0.8	6
581	Manejo sistmico adyuvante en pacientes con cncer de mama y enfermedad residual invasiva posterior a quimioterapia neoadyuvante. Actualizacin de la Evidencia y Abordaje Teraputico en el Instituto Nacional de Cancerologa, Bogot-Colombia. <i>Revista Colombiana De Cancerologa</i> , 0, 25, 160-166.	0.0	0
582	Relationship Between Breast and Axillary Pathologic Complete Response in Women Receiving Neoadjuvant Chemotherapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 5495-5506.	0.7	7
583	The relevance of macrocytosis induction during neoadjuvant dose-dense chemotherapy in breast cancer patients. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	0
584	De-escalating Local Treatment for Women with Breast Cancer. <i>Indian Journal of Surgery</i> , 0, , 1.	0.2	0
585	De-Escalating Axillary Surgery in Node-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. <i>Breast Care</i> , 2021, 16, 1-6.	0.8	4
586	Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. <i>Current Oncology Reports</i> , 2021, 23, 128.	1.8	18
587	A Case Report of an Emergency Hypertensive Episode During Trastuzumab Therapy. <i>Cureus</i> , 2021, 13, e17015.	0.2	0
588	Physicians's Perception of the Evidence in Relation to Primary Endpoints of Clinical Trials on Breast Cancer. <i>Breast Care</i> , 2022, 17, 180-187.	0.8	0
589	Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. <i>Drugs and Aging</i> , 2021, 38, 829-844.	1.3	0
590	Breast Cancer in Jamaica: Stage, Grade and Molecular Subtype Distributions Across Age Blocks, the Implications for Screening and Treatment. <i>World Journal of Oncology</i> , 2021, 12, 93-103.	0.6	10

#	ARTICLE	IF	CITATIONS
591	Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE. <i>Annals of Oncology</i> , 2021, 32, 1005-1014.	0.6	63
592	Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort. <i>Breast</i> , 2021, 58, 106-112.	0.9	6
593	Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME). <i>ESMO Open</i> , 2021, 6, 100220.	2.0	15
594	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. <i>Lancet Oncology</i> , 2021, 22, 1139-1150.	5.1	147
595	First Surgical National Consensus Conference of the Italian Breast Surgeons association (ANISC) on breast cancer management in neoadjuvant setting: Results and summary. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1913-1919.	0.5	3
596	Emerging Biomarkers and Targeted Therapies in Feline Mammary Carcinoma. <i>Veterinary Sciences</i> , 2021, 8, 164.	0.6	6
597	Co-delivery systems: hope for clinical application?. <i>Drug Delivery and Translational Research</i> , 2022, 12, 1339-1354.	3.0	7
598	Recombinant immunotoxins development for HER2-based targeted cancer therapies. <i>Cancer Cell International</i> , 2021, 21, 470.	1.8	16
599	The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer. <i>European Journal of Cancer</i> , 2021, 154, 175-189.	1.3	24
600	Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer. <i>Cancers</i> , 2021, 13, 4884.	1.7	11
601	Application of conventional ultrasonography combined with contrast-enhanced ultrasonography in the axillary lymph nodes and evaluation of the efficacy of neoadjuvant chemotherapy in breast cancer patients. <i>British Journal of Radiology</i> , 2021, 94, 20210520.	1.0	6
602	Integrated Analysis of the Expression Characteristics, Prognostic Value, and Immune Characteristics of PPAR γ in Breast Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 737656.	1.1	6
603	Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113854.	6.6	12
604	Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature. <i>Cancers</i> , 2021, 13, 4894.	1.7	6
605	An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. <i>Molecules</i> , 2021, 26, 5847.	1.7	158
606	Molecular Pathology of Breast Tumors. <i>Surgical Pathology Clinics</i> , 2021, 14, 455-471.	0.7	2
607	Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 1356-1364.	2.9	3
608	Breast cancer treatment-related cardiovascular disturbances: advocacy for a watchful attitude in this never-ending story. <i>Expert Opinion on Drug Safety</i> , 2021, , 1-13.	1.0	0

#	ARTICLE	IF	CITATIONS
609	Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China. <i>Journal of Oncology</i> , 2021, 2021, 1-8.	0.6	1
610	Acute eosinophilic pneumonia: a fatal reaction to ado-trastuzumab. <i>BMJ Case Reports</i> , 2021, 14, e243881.	0.2	2
611	Adjuvant Treatment for Small-Size, Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Escalation or De-Escalation?. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01716.	0.8	1
612	Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1654.	3.4	42
613	Knockout of Calcyclin Binding Protein Impedes the Growth of Breast Cancer Cells by Regulating Cell Apoptosis and β -Catenin Signaling. <i>DNA and Cell Biology</i> , 2021, 40, 1317-1324.	0.9	2
614	The management of HER2-positive early breast cancer: Current and future therapies. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 3-12.	0.7	7
615	Reply to M. Tanaka et al. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01967.	0.8	0
617	Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. <i>Cancer Treatment Reviews</i> , 2021, 99, 102229.	3.4	15
618	Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1360.	3.4	30
619	The Role of Non-Coding RNAs in Breast Cancer Drug Resistance. <i>Frontiers in Oncology</i> , 2021, 11, 702082.	1.3	11
621	Dissecting the biological heterogeneity of HER2-positive breast cancer. <i>Breast</i> , 2021, 59, 339-350.	0.9	41
622	Are all taxanes equal in patients with HER2-positive breast cancer? PERUSing the safety and efficacy of trastuzumab plus pertuzumab and taxanes in real-life usual care. <i>Annals of Oncology</i> , 2021, 32, 1206-1208.	0.6	0
623	Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer – A retrospective cohort study. <i>Breast</i> , 2021, 59, 67-75.	0.9	22
624	How we treat HER2-positive brain metastases. <i>ESMO Open</i> , 2021, 6, 100256.	2.0	24
625	Systemic therapy for older patients with early breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 100, 102292.	3.4	5
626	Management of the axilla and the breast after neoadjuvant chemotherapy in patients with breast cancer: A systematic review. <i>Sisli Etfal Hastanesi Tip Bulteni</i> , 2021, 55, 156-161.	0.1	1
628	Research Progress of Antibody-Drug Conjugate. <i>Advances in Clinical Medicine</i> , 2021, 11, 4135-4143.	0.0	2
629	Future Directions in the Treatment of Osteosarcoma. <i>Cells</i> , 2021, 10, 172.	1.8	102

#	ARTICLE	IF	CITATIONS
630	Trends in neoadjuvant chemotherapy versus surgery-first in stage I HER2-positive breast cancer patients in the National Cancer DataBase (NCDB). <i>Breast Cancer Research and Treatment</i> , 2021, 187, 177-185.	1.1	6
631	Clinicopathologic profile of breast cancer patients treated with neoadjuvant chemotherapy at HUCFF/UFRJ. <i>Mastology</i> , 0, 31, .	0.1	1
632	Safety and efficacy of trastuzumab emtansine (TDM-1) in a patient on hemodialysis for renal failure. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100314.	0.7	2
633	The Progress and Safety Assessment of T-DM1 in Solid Tumor Research. <i>Advances in Clinical Medicine</i> , 2021, 11, 2663-2669.	0.0	0
634	Primary/Neoadjuvant Treatments. , 2021, , 165-182.		0
635	Pathologic Complete Response as a Surrogate Endpoint in Breast Cancer. <i>Touch Reviews in Oncology & Haematology</i> , 2021, 17, 12.	0.1	0
636	Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. <i>Breast Cancer: Basic and Clinical Research</i> , 2021, 15, 117822342199585.	0.6	22
637	Advances in EGFR/HER2-directed clinical research on breast cancer. <i>Advances in Cancer Research</i> , 2020, 147, 375-428.	1.9	8
638	Pathologic response at the epicenter of the treatment decision-making process in Human Epidermal Receptorâ€“Type 2 overexpressing (Her2+) Early Breast Cancer (EBC): Challenges and opportunities for financially-constrained healthcare systems. <i>Breast</i> , 2020, 54, 331-334.	0.9	2
639	The Devastating Impact of the COVID-19 Pandemic on Breast Cancer Care Among Medically Underserved Populations at Two New York City Public Hospitals. <i>Annals of Surgery Open</i> , 2020, 1, e018.	0.7	2
640	Adjuvant Trastuzumab Emtansine (T-DM1) and Concurrent Radiotherapy for Residual Invasive HER2-positive Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 895-901.	0.6	16
641	Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy. <i>Annals of Surgery</i> , 2022, 275, 576-581.	2.1	38
642	Targeting the Human Epidermal Growth Factor Receptor Family in Breast Cancer beyond HER2. <i>Breast Care</i> , 2020, 15, 579-585.	0.8	9
643	Impact of obesity on safety outcomes and treatment modifications with ado-trastuzumab emtansine in breast cancer patients. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 49-54.	0.5	5
644	Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future. <i>Breast Cancer: Basic and Clinical Research</i> , 2020, 14, 117822342098037.	0.6	50
645	Enfortumab Vedotin in urothelial cancer. <i>Therapeutic Advances in Urology</i> , 2020, 12, 175628722098019.	0.9	24
646	Locoregional Management After Neoadjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 2281-2289.	0.8	35
647	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2020, 38, 1081.	0.8	101

#	ARTICLE	IF	CITATIONS
648	Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors. <i>Drugs of Today</i> , 2019, 55, 575.	0.7	30
649	Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting. <i>Oncotarget</i> , 2020, 11, 2083-2091.	0.8	7
650	The efficacy of ado-trastuzumab emtansine in patients with ERBB2-aberrant non-small cell lung cancer: a systematic review. <i>Translational Cancer Research</i> , 2020, 9, 4507-4516.	0.4	6
651	Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy?. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 878-891.	0.7	5
652	Axillary management after neoadjuvant treatment. <i>Minerva Chirurgica</i> , 2020, 75, 400-407.	0.8	3
653	Six versus 12 monthsâ€™ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-190.	1.3	11
654	Neoadjuvant immunotherapy in breast cancer: a paradigm shift?. <i>Ecancermedalscience</i> , 2020, 14, 1147.	0.6	12
655	DHA Affects Microtubule Dynamics Through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell Lines. <i>Cells</i> , 2020, 9, 1260.	1.8	12
656	Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer. <i>Annals of Breast Cancer and Therapy</i> , 2020, 4, 48-57.	0.8	11
657	An overview of immune checkpoint inhibitors in breast cancer. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, .	0.5	4
658	Major clinical research advances in gynecologic cancer in 2019. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e48.	1.0	10
659	Cardiotoxicity of anthracycline-free targeted oncological therapies in HER2-positive breast cancer (Review). <i>Oncology Letters</i> , 2020, 21, 100.	0.8	3
660	Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer. <i>Journal of Carcinogenesis</i> , 2019, 18, 5.	2.5	4
661	Therapeutic significance of hormone receptor positivity in patients with HER-2 positive breast cancer. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2019, 163, 285-292.	0.2	6
662	The choice of a neoadjuvant chemotherapy cycle for breast cancer has significance in clinical practice: results from a population-based, real world study. <i>Cancer Biology and Medicine</i> , 2021, 19, 755-767.	1.4	4
663	Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody-drug conjugates. <i>Chemical Science</i> , 2021, 12, 13613-13647.	3.7	46
664	Neoadjuvant pertuzumab plus trastuzumab in combination with anthracycline-free chemotherapy regimen in patients with HER2 positive breast cancerâ€™Real-world data from a single center in India. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100483.	0.7	7
665	An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2-Antibody-Drug Conjugate against Refractory HER2-Positive Cancers. <i>Advanced Science</i> , 2021, 8, e2102414.	5.6	10

#	ARTICLE	IF	CITATIONS
666	Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates. <i>JAMA Oncology</i> , 2021, 7, 1873.	3.4	66
667	To Look or Not to Look? Axillary Imaging: Less May Be More. <i>Journal of Breast Imaging</i> , 2021, 3, 666-671.	0.5	5
668	Exosomal miRNA profiles of triple-negative breast cancer in neoadjuvant treatment. <i>Oncology Letters</i> , 2021, 22, 819.	0.8	24
669	Hyperpolarized Carbon-13 MRI for Early Response Assessment of Neoadjuvant Chemotherapy in Breast Cancer Patients. <i>Cancer Research</i> , 2021, 81, 6004-6017.	0.4	25
670	Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1+ tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. <i>Future Oncology</i> , 2021, 17, 4665-4676.	1.1	8
671	Analysis of mammograms using artificial intelligence to predict response to neoadjuvant chemotherapy in breast cancer patients: proof of concept. <i>European Radiology</i> , 2022, 32, 3131-3141.	2.3	10
672	Screening and predicted value of potential biomarkers for breast cancer using bioinformatics analysis. <i>Scientific Reports</i> , 2021, 11, 20799.	1.6	29
673	Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials. <i>Cancers</i> , 2021, 13, 5198.	1.7	10
674	Contemporary Outcomes After Multimodality Therapy in Patients With Breast Cancer Presenting With Ipsilateral Supraclavicular Node Involvement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 66-74.	0.4	9
675	Laser Capture Proteomics: spatial tissue molecular profiling from the bench to personalized medicine. <i>Expert Review of Proteomics</i> , 2021, 18, 845-861.	1.3	19
676	A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 51-61.	1.1	24
677	SAVI SCOUT® localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 107-114.	1.1	15
678	Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives. <i>Pharmaceutics</i> , 2021, 13, 1705.	2.0	11
681	Neoadjuvant therapy for HER2-positive breast cancer. , 2019, 10, 83-90.	0.0	0
682	Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management. <i>Journal of the Advanced Practitioner in Oncology</i> , 2019, 10, .	0.2	1
685	The evolving role of pathologic complete response in breast cancer. <i>South Asian Journal of Cancer</i> , 2019, 08, 210-211.	0.2	2
687	Postneoadjuvant therapy: a new approach to the treatment of HER2-positive breast cancer (KATHERINE) Tj ETQq0 0,0 rgBT /Overlock 100	0.1	1
689	Narrowing the focus: Therapeutic cell surface targets for refractory triple-negative breast cancer. <i>World Journal of Clinical Oncology</i> , 2020, 11, 169-179.	0.9	1

#	ARTICLE	IF	CITATIONS
690	2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina. <i>Bosnian Journal of Basic Medical Sciences</i> , 2021, 21, 120-135.	0.6	2
692	<p>Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 3145-3153.	0.9	2
693	Strategy of post-neoadjuvant treatment of patients with residual breast cancer. <i>Opuholi Zenskoj Reproktivnoy Sistemoy</i> , 2020, 16, 43-54.	0.1	3
694	Construction of SIRT1 gene shRNA lentivirus vector and its effect on the proliferation of breast cancer cells. <i>Cellular and Molecular Biology</i> , 2020, 66, 204-210.	0.3	0
695	Nuclear medicine in precision oncology: a foreword. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 231-233.	0.4	0
696	Preclinical Assessment of Paclitaxel- and Trastuzumab-Delivering Magnetic Nanoparticles Fe3O4 for Treatment and Imaging of HER2-Positive Breast Cancer. <i>Frontiers in Medicine</i> , 2021, 8, 738775.	1.2	4
697	Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 303-317.	1.1	10
698	Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period. <i>Breast Care</i> , 2022, 17, 264-271.	0.8	4
699	U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review. <i>Clinical Cancer Research</i> , 2022, 28, 1072-1086.	3.2	31
700	Position Paper on the Value of Extended Adjuvant Therapy with Neratinib for Early HER2+/HR+ Breast Cancer. <i>Breast Care</i> , 2021, 16, 664-676.	0.8	1
701	Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 741451.	1.6	7
702	Adjuvant Therapy. , 2022, , 435-438.		0
703	Revisiting neoadjuvant therapy in non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2021, 22, e501-e516.	5.1	86
705	Ongoing clinical trials on axillary management. <i>Minerva Chirurgica</i> , 2020, 75, 408-418.	0.8	3
706	Neoadjuvant docetaxel with or without carboplatin plus dual HER2 blockade for HER2-positive breast cancer: a retrospective multi-center Chinese study. <i>Gland Surgery</i> , 2020, 9, 2079-2090.	0.5	15
707	The role of the neoadjuvant approach in the treatment of primary operable HER2 positive breast cancer. <i>Malignant Tumours</i> , 2020, 10, 45-52.	0.1	1
708	Economic Evaluation of Adjuvant Trastuzumab Emtansine in Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease after Neoadjuvant Taxane and Trastuzumab-Based Treatment in Canada. <i>Current Oncology</i> , 2020, 27, 578-589.	0.9	4
710	Surgical Treatment After Neoadjuvant Systemic Therapy in Young Women With Breast Cancer. <i>Annals of Surgery</i> , 2022, 276, 173-179.	2.1	20

#	ARTICLE	IF	CITATIONS
711	Immunopathology and Immunotherapy for Breast Cancer. , 2020, , 541-555.		1
712	Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. ESMO Open, 2020, 5, e000880.	2.0	4
713	Tumors: Breast. , 2020, , 1-8.		0
714	Same Story with Different Endings in HER2- Positive Breast Cancer: Why the Benefit of Pertuzumab is Robust in the Metastatic Scenario and Modest in the Adjuvant Setting?. Surgical Medicine Open Access Journal, 2020, 3, .	0.1	0
715	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
717	Ado-Trastuzumab Emtansine “ The Monoclonal Drug Conjugate in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 218-220.	0.1	0
718	Comparative effectiveness and tolerability of targeted agents combined with chemotherapy in patients with HER2-positive gastroesophageal cancer: A network meta-analysis. Saudi Journal of Gastroenterology, 2021, .	0.5	0
719	Improving Outcomes in HER2-Positive Breast Cancer: Analysis and Application of Evolving Data and Best Practices. Journal of the Advanced Practitioner in Oncology, 2020, 11, 271-274.	0.2	0
720	360 Health Analysis (H360) “ A Proposal for an Integrated Vision of Breast Cancer in Portugal. The Journal of Breast Health, 2020, 16, 91-98.	0.4	2
721	Innovative Standards in Surgery of the Breast after Neoadjuvant Systemic Therapy. Breast Care, 2021, 16, 590-597.	0.8	1
722	Multidisciplinary Management of Breast Cancer With Extensive Regional Nodal Involvement. Journal of Clinical Oncology, 2020, 38, 2290-2298.	0.8	2
723	Multidisciplinary Locoregional Management of Breast Cancer. Journal of Clinical Oncology, 2020, 38, 2217-2219.	0.8	3
724	Post-neoadjuvant treatment of breast cancer. Meditsinskiy Sovet, 2020, , 232-241.	0.1	0
726	Neoadjuvant therapy for breast cancer. Value of residual disease. Medical Alphabet, 2020, , 30-33.	0.0	3
728	Case of HER2neu+ Invasive Pleomorphic Lobular Carcinoma With Response to Conventional Neoadjuvant Chemotherapy: A Viable Option for an Exceedingly Rare Breast Cancer Type. Cureus, 2020, 12, e11108.	0.2	0
729	Comprehensive treatment of early breast cancer. Onkologie (Czech Republic), 2020, 14, 148-156.	0.0	0
731	Antibody-drug conjugates: an evolving approach for melanoma treatment. Melanoma Research, 2021, 31, 1-17.	0.6	4
732	Local and regional therapy considerations after preoperative therapy in patients with breast cancer. Current Opinion in Obstetrics and Gynecology, 2021, 33, 59-63.	0.9	0

#	ARTICLE	IF	CITATIONS
733	Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2-Positive Breast Cancer. <i>JAMA Network Open</i> , 2020, 3, e2027074.	2.8	10
734	Trastuzumab emtansine for residual invasive human epidermal growth receptor-2-positive breast cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 652-653.	0.1	0
735	Postneoadjuvant Pure and Predominantly Pure Intralymphatic Breast Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 537-542.	2.1	3
736	Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management. <i>Journal of the Advanced Practitioner in Oncology</i> , 2019, 10, 136-153.	0.2	1
737	Role of WDR5 in breast cancer prognosis. <i>EXCLI Journal</i> , 2019, 18, 1094-1096.	0.5	0
738	The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. <i>American Journal of Cancer Research</i> , 2020, 10, 1045-1067.	1.4	25
739	Mammakarzinom. , 2022, , 340-351.		0
740	Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 165-182.	157.7	132
741	Biomarkers Changes after Neoadjuvant Chemotherapy in Breast Cancer: A Seven-Year Single Institution Experience. <i>Diagnostics</i> , 2021, 11, 2249.	1.3	7
742	Risk Factors, Prognostic Factors, and Nomogram for Distant Metastasis in Breast Cancer Patients Without Lymph Node Metastasis. <i>Frontiers in Endocrinology</i> , 2021, 12, 771226.	1.5	18
743	Accelerating progress to innovation for patients: Trial design and risk stratification. <i>Breast</i> , 2021, , .	0.9	0
744	Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. <i>Current Oncology</i> , 2021, 28, 4894-4928.	0.9	0
745	The tumor immune microenvironment of primary and metastatic HER2+ positive breast cancers utilizing gene expression and spatial proteomic profiling. <i>Journal of Translational Medicine</i> , 2021, 19, 480.	1.8	17
746	Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature. <i>Oncology and Therapy</i> , 2021, , 1.	1.0	4
747	Pathology after neoadjuvant treatment – How to assess residual disease. <i>Breast</i> , 2022, 62, S25-S28.	0.9	18
748	Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer. <i>Molecular Cancer</i> , 2021, 20, 151.	7.9	9
750	Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments. <i>Cancers</i> , 2021, 13, 5771.	1.7	6
751	A Multidisciplinary Approach to Managing Uncertainty. <i>Current Breast Cancer Reports</i> , 2021, 13, 365-380.	0.5	0

#	ARTICLE	IF	CITATIONS
752	The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. <i>Molecular Oncology</i> , 2022, 16, 2355-2366.	2.1	3
753	Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience. <i>Future Oncology</i> , 2022, 18, 323-331.	1.1	2
754	Antibody-drug conjugates in treating older patients suffering from cancer: what is the real value?. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5575-5578.	1.4	2
756	Healthcare Resource Utilization and Costs for Metastatic Breast Cancer Patients Newly Treated with Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Agents. <i>Clinical Breast Cancer</i> , 2021, , .	1.1	1
757	Localized delivery of immunotherapy via implantable scaffolds for breast cancer treatment. <i>Journal of Controlled Release</i> , 2022, 341, 399-413.	4.8	16
758	Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response. <i>Clinical Cancer Research</i> , 2022, 28, 697-707.	3.2	17
759	Adjuvant abemaciclib for high-risk breast cancer: the story continues. <i>Annals of Oncology</i> , 2021, 32, 1457-1459.	0.6	2
760	Microbial transglutaminase nanoflowers as an alternative nanomedicine for breast cancer theranostics. <i>RSC Advances</i> , 2021, 11, 34613-34630.	1.7	4
761	Non-cleavable Linkers: Permanently Linked, for Better or for Worse. <i>RSC Drug Discovery Series</i> , 2021, , 136-172.	0.2	0
762	Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110595.	1.4	10
763	Tumors: Breast. , 2021, , 5215-5222.		0
764	Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial. <i>Tumori</i> , 2022, , 030089162110675.	0.6	1
765	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. <i>EBioMedicine</i> , 2022, 75, 103801.	2.7	47
766	Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. <i>Annals of Surgical Oncology</i> , 2022, 29, 1489-1492.	0.7	15
767	Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 117-124.	0.4	11
768	Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential. , 2022, 236, 108106.		16
769	Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 1.	2.3	17
770	Lack of racial differences in clinical outcomes of breast cancer patients receiving neoadjuvant chemotherapy: a single academic center study. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 411-421.	1.1	4

#	ARTICLE	IF	CITATIONS
771	Targeting brain metastases in breast cancer. <i>Cancer Treatment Reviews</i> , 2022, 103, 102324.	3.4	46
772	De-Escalation of Breast Cancer Surgery Following Neoadjuvant Systemic Therapy. <i>The Journal of Breast Health</i> , 2022, 18, 6-12.	0.4	4
773	Mammakarzinom: Update 2019. , 0, , .		0
775	Histopathological examination of surgical breast cancer specimens after neoadjuvant chemotherapy using digital radiography. <i>Russian Journal of Oncology</i> , 2020, 25, 219-226.	0.1	1
776	Updates in HER2-Positive and Triple-Negative Breast Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 605-609.	2.3	2
777	Clinical Consequences of Altering the Definition of HER2-Positive Breast Cancer to Exclude Group 2, HER2-Negative Disease. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, xxii.	2.3	1
778	Surgical Management of the Axilla in Node-Negative and Node-Positive Disease at Diagnosis. , 2022, , 207-218.		0
779	Antibody-drug conjugates in HER2-positive breast cancer. <i>Chinese Medical Journal</i> , 2022, 135, 261-267.	0.9	21
780	Updated Austrian treatment algorithm in HER2+ metastatic breast cancer. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 63-72.	1.0	1
781	A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells. <i>MBio</i> , 2022, 13, e0338421.	1.8	4
782	Aiming at a Tailored Cure for <i>ERBB2</i> -Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2022, 8, 629.	3.4	18
783	Bioresponsive nanogels for protein delivery. <i>View</i> , 2022, 3, .	2.7	26
784	Flubendazole Plays an Important Anti-Tumor Role in Different Types of Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 519.	1.8	7
785	Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer. <i>Cancer Research and Treatment</i> , 2022, 54, 1130-1137.	1.3	4
786	Utilization of neoadjuvant chemotherapy in high-risk, node-negative early breast cancer. <i>Cancer Medicine</i> , 2022, 11, 1099-1108.	1.3	6
787	Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies. <i>Oncologist</i> , 2022, 27, 30-39.	1.9	10
788	How Often Does Retrieval of a Clipped Lymph Node Change Adjuvant Therapy Recommendations? A Prospective, Consecutive, Patient Cohort Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 3764-3771.	0.7	6
789	Intramedullary spinal cord metastasis to the cauda equina in a patient with HER2-positive metastatic breast cancer: A case report. <i>Breast Disease</i> , 2022, 41, 155-161.	0.4	2

#	ARTICLE	IF	CITATIONS
790	Surrogacy Beyond Prognosis: The Importance of "Trial-Level" Surrogacy. <i>Oncologist</i> , 2022, 27, 266-271.	1.9	29
791	A Novel Inflammatory-Nutritional Prognostic Scoring System for Patients with Early-Stage Breast Cancer. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 381-394.	1.6	13
792	HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping. <i>Cancers</i> , 2022, 14, 512.	1.7	2
793	Predictive and prognostic significance of BRCAness in HER2-negative breast cancer. <i>Breast Cancer</i> , 2022, 29, 368-376.	1.3	3
794	Sociodemographic and Clinical Predictors of Neoadjuvant Chemotherapy in cT1-T2/NO HER2-Amplified Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 3051-3061.	0.7	3
796	Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. <i>Breast</i> , 2022, 62, S12-S16.	0.9	29
797	Updates on breast biomarkers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 163-176.	1.4	33
798	ABC6 Consensus: Assessment by a Group of German Experts. <i>Breast Care</i> , 2022, 17, 90-100.	0.8	6
799	Application of Microfluidic Systems for Breast Cancer Research. <i>Micromachines</i> , 2022, 13, 152.	1.4	6
800	Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies. <i>CNS Drugs</i> , 2022, 36, 167-179.	2.7	6
801	Biomimetic Nanoerythroosome-Coated Aptamer-DNA Tetrahedron/Maytansine Conjugates: pH-Responsive and Targeted Cytotoxicity for HER2-Positive Breast Cancer. <i>Advanced Materials</i> , 2022, 34, e2109609.	11.1	158
802	Misconception on the duration of ado-trastuzumab emtansine treatment for HER2-positive early breast cancer. <i>American Journal of Health-System Pharmacy</i> , 2022, , .	0.5	0
803	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. <i>Lancet Oncology</i> , The, 2022, 23, 149-160.	5.1	148
804	Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer. <i>Advances in Therapy</i> , 2022, 39, 1375-1392.	1.3	3
805	Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience. <i>Cancer Research and Treatment</i> , 2022, , .	1.3	8
806	Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110666.	1.4	16
807	Think Globally, Start Locally: Value-Based Breast Cancer Care for Newly Diagnosed Patients in A Safety-Net Medical Center. <i>International Journal of Cancer Care and Delivery</i> , 2022, 2, .	0.0	0
808	Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases. <i>Cancers</i> , 2022, 14, 533.	1.7	4

#	ARTICLE	IF	CITATIONS
809	Terapia personalizada en c�ncer de mama precoz. Implicancias pr�cticas. Revista M�dica Cl�nica Las Condes, 2022, 33, 17-24.	0.2	0
810	Novel development strategies and challenges for anti-Her2 antibody-drug conjugates. Antibody Therapeutics, 2022, 5, 18-29.	1.2	8
811	Neoadjuvant Chemotherapy for Metaplastic Breast Cancer: Response Rates, Management, and Outcomes. Clinical Breast Cancer, 2022, 22, e691-e699.	1.1	13
812	Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer. Bioconjugate Chemistry, 2022, 33, 418-426.	1.8	3
813	Evolution of low HER2 expression between early and advanced-stage breast cancer. European Journal of Cancer, 2022, 163, 35-43.	1.3	88
814	Radiotherapy and newly approved cancer drugs – A quantitative analysis of registered protocols for drugs approved for the treatment of solid tumors. Radiotherapy and Oncology, 2022, 168, 69-74.	0.3	0
815	Safety of pre- or postoperative accelerated radiotherapy in 5 fractions: A randomized pilot trial. Breast, 2022, 62, 10-15.	0.9	2
816	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. Journal of Clinical Oncology, 2022, 40, 438-448.	0.8	35
817	Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience. Breast Cancer Research and Treatment, 2022, 192, 563-571.	1.1	2
818	Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Frontiers in Oncology, 2021, 11, 827625.	1.3	7
819	Adjuvant treatment for breast cancer. Surgery, 2022, 40, 132-138.	0.1	0
820	Predictors of axillary node response in node-positive patients undergoing neoadjuvant chemotherapy for breast cancer. Canadian Journal of Surgery, 2022, 65, E89-E96.	0.5	2
821	Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy. Journal of Personalized Medicine, 2022, 12, 261.	1.1	4
822	The Impact of Post-Mastectomy Radiotherapy on Survival Outcomes in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy. Cancers, 2021, 13, 6205.	1.7	6
823	Combination of Modern Radiotherapy and New Targeted Treatments for Breast Cancer Management. Cancers, 2021, 13, 6358.	1.7	8
824	Mammaerkrankungen. , 2021, , 297-361.		0
825	Tisotumab Vedotin in Cervical Cancer: Current Status and Future Perspectives. Touch Reviews in Oncology & Haematology, 2021, 17, 68.	0.1	0
826	Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis. BJS Open, 2022, 6, .	0.7	21

#	ARTICLE	IF	CITATIONS
827	Neurological complications of immunotherapy and monoclonal antibody therapy. , 2022, , 521-536.		0
829	Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210791.	1.4	3
830	Management of breast cancer in older patients. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 682-689.	0.6	3
831	Stratification of Prognosis by Biological Features Following Neoadjuvant Chemotherapy in Luminal Breast Cancer. <i>In Vivo</i> , 2022, 36, 859-864.	0.6	0
832	Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinical Investigation to Clinic. <i>Cancers</i> , 2022, 14, 1198.	1.7	29
833	Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland. <i>Cancers</i> , 2022, 14, 1218.	1.7	2
834	Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel. <i>Cancers</i> , 2022, 14, 1022.	1.7	10
835	Opportunities in combinational chemo-immunotherapy for breast cancer using nanotechnology: an emerging landscape. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 247-268.	2.4	8
836	Breast cancer management in 2021: A primer for the obstetrics and gynecology. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2022, 82, 30-45.	1.4	18
837	Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. <i>Cancers</i> , 2022, 14, 1253.	1.7	69
838	Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs. <i>ChemistrySelect</i> , 2022, .	0.7	3
839	A pharmacokinetic study to comparatively evaluate the bioequivalence and safety of a humanized recombinant monoclonal antibody targeting human epidermal growth factor receptor-2 with the reference Herceptin in healthy Chinese subjects. <i>Investigational New Drugs</i> , 2022, , 1.	1.2	0
841	Identifying and Validating of an Autophagy-Related Gene Signature for the Prediction of Early Relapse in Breast Cancer. <i>Frontiers in Endocrinology</i> , 2022, 13, 824362.	1.5	3
842	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. <i>Npj Breast Cancer</i> , 2022, 8, 18.	2.3	8
843	Post-Neoadjuvant Treatment Strategies in Breast Cancer. <i>Cancers</i> , 2022, 14, 1246.	1.7	8
844	New antibody-drug conjugates (ADCs) in breast cancer—“an overview of ADCs recently approved and in later stages of development. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 27-36.	0.5	15
845	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. <i>Npj Breast Cancer</i> , 2022, 8, 37.	2.3	9
846	Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab. <i>Frontiers in Oncology</i> , 2022, 12, 819818.	1.3	3

#	ARTICLE	IF	CITATIONS
847	Bystander effect of antibody-drug conjugates: fact or fiction?. <i>Current Oncology Reports</i> , 2022, 24, 809-817.	1.8	35
848	Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. <i>JCO Precision Oncology</i> , 2022, 6, e2000368.	1.5	9
849	Management of early stage HER2 positive breast cancer and increased implementation of axillary imaging to improve identification of nodal metastasis. <i>Journal of Surgical Oncology</i> , 2022, 125, 1218-1223.	0.8	2
850	Gene expression trend changes in breast cancer populations over two decades: insights from The Cancer Genome Atlas database. <i>Hereditas</i> , 2022, 159, 18.	0.5	4
851	Gene signatures in patients with early breast cancer and relapse despite pathologic complete response. <i>Npj Breast Cancer</i> , 2022, 8, 42.	2.3	9
852	Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease. <i>Journal of Neuro-Oncology</i> , 2022, 157, 249-269.	1.4	9
853	Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth. <i>Nature Biomedical Engineering</i> , 2022, 6, 257-266.	11.6	32
854	Antibody-drug conjugates targeting CD248 inhibits liver fibrosis through specific killing on myofibroblasts. <i>Molecular Medicine</i> , 2022, 28, 37.	1.9	4
856	mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1108-1121.	1.5	5
857	Underserved groups remain underserved as eligibility criteria routinely exclude them from breast cancer trials. <i>Journal of Clinical Epidemiology</i> , 2022, 147, 132-141.	2.4	5
858	HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 834651.	1.6	63
859	Breast Radiotherapy after Oncoplastic Surgery—A Multidisciplinary Approach. <i>Cancers</i> , 2022, 14, 1685.	1.7	2
860	Neoadjuvant Therapy in Breast Cancer. <i>Surgical Pathology Clinics</i> , 2022, 15, 57-75.	0.7	5
861	Evaluating Regional Nodal Irradiation Allocation and Association with Oncologic Outcomes in NSABP B-18, B-27, B-40, and B-41. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 542-551.	0.4	7
862	Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. <i>ESMO Open</i> , 2022, 7, 100409.	2.0	25
863	Variation over time of the factors influencing return to work and work capacities after a diagnosis of breast cancer: a study on the behalf of the Seintinelles research network. <i>Supportive Care in Cancer</i> , 2022, 30, 5991-5999.	1.0	5
864	Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1195-1209.	1.2	16
865	The association between body mass index and pathological complete response in neoadjuvant-treated breast cancer patients. <i>Acta Oncol</i> , 2022, 61, 731-737.	0.8	0

#	ARTICLE	IF	CITATIONS
866	Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. <i>Cancer Treatment Reviews</i> , 2022, 105, 102375.	3.4	82
867	Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC. <i>Breast</i> , 2022, 63, 177-186.	0.9	3
868	Clinical trial data and emerging strategies: HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 281-291.	1.1	12
869	Cardioprotection for Anti-HER2 Therapy: Considerations for Primary Prevention and Use in Mildly Reduced Left Ventricular Ejection Fraction. <i>Current Oncology Reports</i> , 2022, 24, 1063-1070.	1.8	3
870	Template-Assisted Antibody Assembly: A Versatile Approach for Engineering Functional Antibody Nanoparticles. <i>Chemistry of Materials</i> , 2022, 34, 3694-3704.	3.2	4
871	Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer – a review of current evidence for and against the use of anti-HER2 treatment regimens. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 505-522.	1.1	1
872	When the clipped node goes missing, CT guided SAVI SCOUT placement: A novel approach for localizing soft tissue targets. <i>Clinical Imaging</i> , 2022, 85, 115-117.	0.8	0
873	Central nervous system disease in phase III studies for advanced HER2 positive breast cancer: A review. <i>Breast</i> , 2022, 63, 85-100.	0.9	5
874	Antibody-drug conjugates targeting CD248 myofibroblasts effectively alleviate renal fibrosis in mice. <i>FASEB Journal</i> , 2022, 36, e22102.	0.2	2
875	Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. <i>BMJ</i> , The, 2021, 375, e066381.	3.0	53
876	Updates on targeting human epidermal growth factor receptor 2-positive breast cancer: what's to know in 2021. <i>Current Opinion in Obstetrics and Gynecology</i> , 2022, 34, 41-45.	0.9	5
878	Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature. <i>Cancers</i> , 2022, 14, 196.	1.7	4
881	Breast cancer – The catalyst of contemporary trials design. <i>Journal of Surgical Oncology</i> , 2022, 125, 7-16.	0.8	0
882	Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer. <i>Meditinskiy Sovet</i> , 2021, , 68-74.	0.1	0
884	Prognostic value of residual cancer burden and Miller-Payne system after neoadjuvant chemotherapy for breast cancer. <i>Gland Surgery</i> , 2021, 10, 3211-3221.	0.5	7
885	Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs. <i>Cancers</i> , 2022, 14, 154.	1.7	30
888	Clinical and Therapeutic Factors Vary by Prognosis in Patients with Pathological Complete Response After Neoadjuvant Therapy for Breast Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 9235-9246.	0.9	3
889	Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement. <i>Tumori</i> , 2022, 108, 196-203.	0.6	6

#	ARTICLE	IF	CITATIONS
890	Locally advanced breast cancer. <i>Breast</i> , 2021, , .	0.9	9
891	Neoadjuvant approach in patients with early breast cancer: patient assessment, staging, and planning. <i>Breast</i> , 2021, , .	0.9	3
892	Pathological responses and survival outcomes in patients with locally advanced breast cancer after neoadjuvant chemotherapy: a single-institute experience. <i>Journal of the Egyptian National Cancer Institute</i> , 2021, 33, 39.	0.6	5
894	Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021. <i>Breast</i> , 2021, , .	0.9	1
896	Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial. <i>Clinical Breast Cancer</i> , 2022, 22, 308-318.	1.1	2
898	Radiotherapy in the Management of Non-Metastatic Inflammatory Breast Cancers: A Retrospective Observational Study. <i>Cancers</i> , 2022, 14, 107.	1.7	3
900	A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 1-20.	1.1	8
901	Concordance between core needle biopsy and surgical excision for breast cancer tumor grade and biomarkers. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 151-159.	1.1	10
903	Anthracyclines in the treatment of patients with early breast cancer. <i>ESMO Open</i> , 2022, 7, 100461.	2.0	4
904	Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective. <i>Current Oncology</i> , 2022, 29, 2720-2734.	0.9	9
905	Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 149-171.	0.5	3
906	Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 751-761.	1.9	10
907	Markers Associated With Tumor Recurrence in Patients With Breast Cancer Achieving a Pathologic Complete Response After Neoadjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 860475.	1.3	5
908	Baseline Mutations and Up-Regulation of PI3K-AKT Pathway Serve as Potential Indicators of Lack of Response to Neoadjuvant Chemotherapy in Stage II/III Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 784985.	1.3	8
909	Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, 538-546.	1.1	5
910	Antibody-Drug Conjugates as an Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2066-2067.	0.8	1
913	False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 589-595.	1.1	14
914	Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 597-612.	1.1	1

#	ARTICLE	IF	CITATIONS
915	Neoadjuvant chemotherapy use trends among older women with breast cancer: 2010–2017. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 695-705.	1.1	3
916	YTHDF1 upregulation mediates hypoxia-dependent breast cancer growth and metastasis through regulating PKM2 to affect glycolysis. <i>Cell Death and Disease</i> , 2022, 13, 258.	2.7	35
918	Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer. <i>Einstein (Sao Paulo, Brazil)</i> , 2022, 20, eGS6655.	0.3	1
919	The Radiological Response Rate Pattern Is Associated With Recurrence Free Survival in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. <i>Journal of Breast Cancer</i> , 2022, 25, 106.	0.8	0
920	A stepwise one-pot synthesis of aliphatic thiols and their derivatives from acrylamides and sulfur. <i>Organic and Biomolecular Chemistry</i> , 2022, 20, 4361-4368.	1.5	2
921	Reconstructing virtual large slides can improve the accuracy and consistency of tumor bed evaluation for breast cancer after neoadjuvant therapy. <i>Diagnostic Pathology</i> , 2022, 17, 40.	0.9	1
922	Hormone Receptor and HER2 Status Switch in Non-pCR Breast Cancer Specimens after Neoadjuvant Therapy. <i>Breast Care</i> , 2022, 17, 501-507.	0.8	0
924	LMOD1, an oncogene associated with Lauren classification, regulates the metastasis of gastric cancer cells through the FAK-AKT/mTOR pathway. <i>BMC Cancer</i> , 2022, 22, 474.	1.1	7
925	Immunohistochemical subtypes of the breast cancer in the ultrasound and clinical aspect – literature review. <i>Journal of Ultrasonography: Official Publication of Polish Ultrasound Society / Red Nacz Iwona SudoÅ, SzopiÅ, ska</i> , 2022, 22, 93-99.	0.7	2
926	Oncobiology and treatment of breast cancer in young women. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 749-770.	2.7	11
927	Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. <i>Cancers</i> , 2022, 14, 2136.	1.7	21
929	Neoadjuvant chemotherapy and radiotherapy for locally advanced breast cancer: Safety and efficacy of reverse sequence compared to standard technique?. <i>European Journal of Surgical Oncology</i> , 2022, , .	0.5	1
930	Rate of pathological complete response in early HER2 breast cancer. <i>Bulletin Du Cancer</i> , 2022, 109, 722-722.	0.6	0
931	Duration of trastuzumab use in patients with early breast cancer. <i>The National Medical Journal of India</i> , 2022, 34, 285-286.	0.1	0
932	Salvia miltiorrhiza in Breast Cancer Treatment: A Review of Its Phytochemistry, Derivatives, Nanoparticles, and Potential Mechanisms. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	11
933	Neoadjuvant Chemotherapy for Nonmetastatic Breast Cancer. <i>Advances in Oncology</i> , 2022, 2, 47-61.	0.1	2
934	Development and Biochemical Characterization of Self-Immolative Linker Containing GnRH-III-Drug Conjugates. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5071.	1.8	6
935	Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/NO HER2+ breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 65.	2.3	5

#	ARTICLE	IF	CITATIONS
936	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022. <i>Breast Care</i> , 2022, 17, 403-420.	0.8	43
937	A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 63.	2.3	18
938	A SYSTEMATIC REVIEW ON SUPERSATURABLE SELF-NANO EMULSIFYING DRUG DELIVERY SYSTEM: A POTENTIAL STRATEGY FOR DRUGS WITH POOR ORAL BIOAVAILABILITY. <i>International Journal of Applied Pharmaceutics</i> , 0, , 16-33.	0.3	2
939	Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67. <i>Annals of Surgical Oncology</i> , 2022, 29, 5747-5756.	0.7	9
942	Treatment of Breast Cancer in Young Adults. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 795-806.	1.8	8
943	A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer. <i>Science China Life Sciences</i> , 2022, 65, 2205-2217.	2.3	7
944	Addressing the problem of overtreatment in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 535-548.	1.1	4
945	Contrast-enhanced mammography predicts pathological response after neoadjuvant chemotherapy in locally advanced breast cancer. <i>Ecancermedicalsecience</i> , 0, 16, .	0.6	2
946	The applications of plasma cell-free DNA in cancer detection: Implications in the management of breast cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 175, 103725.	2.0	1
947	Management of HER2-Positive Early Breast Cancer in Italy: A Maze Presenting Opportunities and Challenges. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	0
948	HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	46
949	Time to surgery delays: Barriers to care for black women with breast cancer. <i>American Journal of Surgery</i> , 2022, 224, 809-810.	0.9	3
950	Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside. <i>Cancer Treatment Reviews</i> , 2022, 108, 102417.	3.4	11
952	The History of Early Breast Cancer Treatment. <i>Genes</i> , 2022, 13, 960.	1.0	16
953	Impact of COVID-19 Disease in Early Breast Cancer Management: A Summary of the Current Evidence. <i>JCO Global Oncology</i> , 2022, , .	0.8	3
954	Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer. <i>Laboratory Investigation</i> , 2022, 102, 1101-1108.	1.7	53
955	Hypertensive events after the initiation of contemporary cancer therapies for breast cancer control. <i>Cancer Medicine</i> , 0, , .	1.3	2
956	Contemporary breast cancer treatment-associated thrombosis. <i>Thrombosis Research</i> , 2022, 213, S8-S15.	0.8	2

#	ARTICLE	IF	CITATIONS
957	Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 2795.	1.7	7
958	Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy. <i>JAMA Oncology</i> , 2022, 8, 1190.	3.4	21
960	Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211065.	1.4	3
961	COVID-19 and its impact on cancer, HIV, and mentally ill patients. , 2022, , 95-137.		1
962	Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 727-48.	0.9	3
963	Multidisciplinary Treatment with Surgery for Locally Advanced Breast Cancer. <i>Kitakanto Medical Journal</i> , 2022, 72, 165-168.	0.0	0
964	Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations. <i>Annals of Surgical Oncology</i> , 2022, 29, 6504-6507.	0.7	1
965	Fertility Preservation in Young Women with Breast Cancer: Impact on Treatment and Outcomes. <i>Annals of Surgical Oncology</i> , 2022, 29, 5786-5796.	0.7	5
966	Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
967	The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 723-734.	2.3	19
968	Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022. <i>JAMA Network Open</i> , 2022, 5, e2216058.	2.8	9
970	Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective. <i>Current Oncology</i> , 2022, 29, 4125-4137.	0.9	2
971	Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies. <i>Cancers</i> , 2022, 14, 3002.	1.7	0
972	Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma. , 2022, 10, e004841.		6
973	Clinical utility of MRI in the neoadjuvant management of early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	4
974	Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 5923-5928.	0.3	0
975	Breast Cancer Epidemiology and Contemporary Breast Cancer Care: A Review of the Literature and Clinical Applications. <i>Clinical Obstetrics and Gynecology</i> , 2022, 65, 461-481.	0.6	6
976	Reversible and Highly Ordered Biointerfaces for Efficient Capture and Nondestructive Release of Circulating Tumor Cells. <i>Analytical Chemistry</i> , 0, , .	3.2	9

#	ARTICLE	IF	CITATIONS
977	Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
978	Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6547.	1.8	11
979	Regional Nodal Management After Preoperative Systemic Therapy. <i>Seminars in Radiation Oncology</i> , 2022, 32, 228-236.	1.0	2
980	Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	12
982	Pertuzumab retreatment for HER2-Positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS). <i>Cancer Science</i> , 2022, 113, 3169-3179.	1.7	8
983	Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2946-2956.	0.8	46
984	Matrix Metalloproteinase-2-Responsive Surface-Changeable Liposomes Decorated by Multifunctional Peptides to Overcome the Drug Resistance of Triple-Negative Breast Cancer through Enhanced Targeting and Penetrability. <i>ACS Biomaterials Science and Engineering</i> , 2022, 8, 2979-2994.	2.6	13
985	Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience. <i>Breast Journal</i> , 2022, 2022, 1-10.	0.4	2
986	Influence of Adjuvant Radiotherapy Timing on Survival Outcomes in High-Risk Patients Receiving Neoadjuvant Treatments. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
987	Fertility Counseling in BRCA1/2-Mutated Women with Breast Cancer and Healthy Individuals. <i>Journal of Clinical Medicine</i> , 2022, 11, 3996.	1.0	4
988	Predictive biomarkers for personalized medicine in breast cancer. <i>Cancer Letters</i> , 2022, 545, 215828.	3.2	14
989	Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I-III Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 7726-7736.	0.7	5
990	Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 3305.	1.7	11
991	Impact of Tumor Progression on Survival During Neoadjuvant Chemotherapy in Breast Cancer: A Cohort Study. <i>Anticancer Research</i> , 2022, 42, 3735-3742.	0.5	2
992	Beyond HER2: Targeting the ErbB receptor family in breast cancer. <i>Cancer Treatment Reviews</i> , 2022, 109, 102436.	3.4	13
993	CACA Guidelines for Holistic Integrative Management of Breast Cancer. , 2022, 1, .		2
994	Breast cancer. De-Escalating Breast Cancer Surgery. <i>Voprosy Onkologii</i> , 2022, 68, 273-285.	0.1	1
995	Does Residual Cancer Burden Predict Local Recurrence After Neoadjuvant Chemotherapy?. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	0

#	ARTICLE	IF	CITATIONS
996	Safety and Tolerability of Metastasis-Directed Radiation Therapy in the Era of Evolving Systemic, Immune, and Targeted Therapies. <i>Advances in Radiation Oncology</i> , 2022, 7, 101022.	0.6	8
997	Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?. <i>European Journal of Cancer</i> , 2022, 171, 25-42.	1.3	9
998	Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan. <i>CNS Oncology</i> , 2022, 11, .	1.2	4
999	A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1000	Neoadjuvant treatment in solid tumors—the earlier, the better in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 0, , .	0.3	1
1001	Locoregional Management of Breast Cancer Following Neoadjuvant Chemotherapy. <i>Current Breast Cancer Reports</i> , 0, , .	0.5	0
1002	Prospective Evaluation of Ultrafast Breast MRI for Predicting Pathologic Response after Neoadjuvant Therapies. <i>Radiology</i> , 2022, 305, 565-574.	3.6	15
1003	Combination of Focused Ultrasound, Immunotherapy, and Chemotherapy. <i>Journal of Ultrasound in Medicine</i> , 2023, 42, 559-573.	0.8	11
1004	Guidelines for breast cancer treatment in Bosnia and Herzegovina. <i>Bosnian Journal of Basic Medical Sciences</i> , 0, , .	0.6	1
1005	Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 171-180.	1.1	3
1006	Is antibody-drug conjugate a rising star for clinical treatment of solid tumors? A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 177, 103758.	2.0	2
1007	Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification. <i>Cancer Biology and Medicine</i> , 2022, 19, 1-5.	1.4	14
1008	Multidisciplinary considerations in the management of breast cancer patients receiving neoadjuvant chemotherapy. <i>Current Problems in Surgery</i> , 2022, 59, 101191.	0.6	0
1009	Are We Overtreating Patients With T1a HER2+ Breast Cancer? An Analysis of the National Cancer Database. <i>Clinical Breast Cancer</i> , 2022, 22, 828-839.	1.1	2
1010	HER2-Targeted Antibody-Drug Conjugates Display Potent Antitumor Activities in Preclinical Extramammary Paget's Disease Models: In Vivo and Immunohistochemical Analyses. <i>Cancers</i> , 2022, 14, 3519.	1.7	1
1011	A Review on Nanocarrier Mediated Treatment and Management of Triple Negative Breast Cancer: A Saudi Arabian Scenario. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1012	De-escalating Surgery Among Patients with HER2+ and Triple Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 0, , .	0.5	4
1013	Nodal Pathologic Complete Response Rates in Luminal Breast Cancer Vary by Genomic Risk. <i>Annals of Surgical Oncology</i> , 2022, 29, 6254-6264.	0.7	2

#	ARTICLE	IF	CITATIONS
1014	Modern Management of Chest Wall Recurrences after Mastectomy. <i>Current Breast Cancer Reports</i> , 0, , .	0.5	0
1015	Sustained Mild Inflammation in Cancer Survivors: Where to from Here?. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	2
1016	What Is the Role of Neoadjuvant Endocrine Therapy for Breast Cancer?. <i>Advances in Surgery</i> , 2022, 56, 275-286.	0.6	2
1017	Is Nodal Clipping Beneficial for Node-Positive Breast Cancer Patients Receiving Neoadjuvant Chemotherapy?. <i>Annals of Surgical Oncology</i> , 2022, 29, 6133-6139.	0.7	10
1018	Association of Pathologic Complete Response and Long-Term Survival Outcomes Among Patients Treated With Neoadjuvant Chemotherapy or Chemoradiotherapy for NSCLC: A Meta-Analysis. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100384.	0.6	8
1019	Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis?—Results from the Adjuvant SUCCESS A Trial. <i>Cancers</i> , 2022, 14, 3949.	1.7	8
1020	Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights. <i>Cancer Management and Research</i> , 0, Volume 14, 2493-2506.	0.9	3
1021	Neoadjuvant Chemotherapy for Breast Cancer: The Ultimate “Spy”. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	1
1022	Breast surgery: a narrative review. <i>Medical Journal of Australia</i> , 2022, 217, 262-267.	0.8	2
1023	Dynamic changes in intrinsic subtype, immunity status, and risk score before and after neoadjuvant chemo- and HER2-targeted therapy without pCR in HER2-positive breast cancers: A cross-sectional analysis. <i>Medicine (United States)</i> , 2022, 101, e29877.	0.4	1
1024	Overcoming Resistance to HER2-Directed Therapies in Breast Cancer. <i>Cancers</i> , 2022, 14, 3996.	1.7	24
1025	One-year recovery from breast cancer: Importance of tumor and treatment-related factors, resilience, and sociodemographic factors for health-related quality of life. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1026	Patients achieved pCR during neoadjuvant chemotherapy had better outcome than adjuvant chemotherapy setting in breast cancer: a comparative study. <i>Cancer Treatment and Research Communications</i> , 2022, , 100618.	0.7	0
1027	A Randomized Controlled Phase 2 Study of Neoadjuvant Eribulin Versus Paclitaxel in Women with Operable Breast Cancer: The JONIE-3 Study. <i>Clinical Breast Cancer</i> , 2022, 22, e881-e891.	1.1	1
1028	Refining therapy in patients with HER2-positive Breast cancer with Central Nervous System metastasis. <i>Breast Care</i> , 0, , .	0.8	0
1029	Long-term follow-up of early stage HER2-positive breast cancer patients treated with trastuzumab: A population-based real world multicenter cohort study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1030	An exploratory study on the checkout rate of circulating tumor cells and the prediction of efficacy of neoadjuvant therapy and prognosis in patients with HER-2-positive early breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1031	Tailoring antiHer2 treatment strategies in breast cancer and beyond. <i>Current Problems in Cancer</i> , 2022, 46, 100892.	1.0	4

#	ARTICLE	IF	CITATIONS
1032	Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy. Archives of Pathology and Laboratory Medicine, 2022, 147, 591-603.	1.2	3
1033	HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer. EBioMedicine, 2022, 83, 104205.	2.7	8
1034	The value of surgical staging of the axilla. Revista De Senologia Y Patologia Mamaria, 2022, , .	0.0	0
1035	Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups. Frontiers in Oncology, 0, 12, .	1.3	2
1036	Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer. Current Oncology, 2022, 29, 5810-5822.	0.9	4
1037	FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 5249-5253.	3.2	18
1038	Antibody drug conjugates (ADCs): an expanding rational treatment paradigm in breast cancer (CME) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.0	0
1040	Residual Cancer Burden Class Associated with Survival Outcomes in Women with Different Phenotypic Subtypes of Breast Cancer After Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 0, , .	0.7	1
1041	Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study. Breast Cancer Research and Treatment, 2022, 195, 301-310.	1.1	5
1042	Predictive Factors of Long-Term Survival after Neoadjuvant Radiotherapy and Chemotherapy in High-Risk Breast Cancer. Cancers, 2022, 14, 4031.	1.7	5
1043	Accuracy and Limitations of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes. Breast Journal, 2022, 2022, 1-8.	0.4	3
1044	How Reliable Are Gene Expression-Based and Immunohistochemical Biomarkers Assessed on a Core-Needle Biopsy? A Study of Paired Core-Needle Biopsies and Surgical Specimens in Early Breast Cancer. Cancers, 2022, 14, 4000.	1.7	6
1045	Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials. BMC Cancer, 2022, 22, .	1.1	1
1046	Different Prognostic Values of Tumour and Nodal Response to Neoadjuvant Chemotherapy Depending on Subtypes of Inflammatory Breast Cancer, a 317 Patient-Study. Cancers, 2022, 14, 3928.	1.7	5
1048	Pertuzumab study in the neoadjuvant setting for HER2-positive nonmetastatic breast cancer in Australia (PeRSIA). International Journal of Cancer, 0, , .	2.3	1
1049	A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting. PharmacoEconomics - Open, 2023, 7, 3-36.	0.9	6
1050	ctDNA for Risk of Recurrence Assessment in Patients Treated with Neoadjuvant Treatment: A Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2022, 29, 8666-8674.	0.7	7
1051	Potential of antibody-drug conjugates (ADCs) for cancer therapy. Cancer Cell International, 2022, 22, .	1.8	36

#	ARTICLE	IF	CITATIONS
1052	Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendations. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 1343-1360.	0.5	3
1054	Evaluation of different imaging modalities for axillary lymph node staging in breast cancer patients to provide a personalized and optimized therapy algorithm. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3457-3467.	1.2	2
1055	Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer. <i>Archives of Pharmacal Research</i> , 2022, 45, 597-617.	2.7	6
1056	Targeted therapy for breast cancer: An overview of drug classes and outcomes. <i>Biochemical Pharmacology</i> , 2022, 204, 115209.	2.0	38
1058	Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 14, 259-280.	1.0	3
1059	Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon. <i>Future Oncology</i> , 2022, 18, 3199-3215.	1.1	10
1060	Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy. <i>JCO Precision Oncology</i> , 2022, , .	1.5	3
1061	Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer. <i>ESMO Open</i> , 2022, 7, 100561.	2.0	6
1063	Toxicity and Timing of Breast Radiation Therapy With Overlapping Systemic Therapies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 377-381.	0.4	2
1064	Concomitant Radiation and Systemic Therapy in the Adjuvant and Metastatic Setting. , 2022, , 421-434.		0
1065	Ampelopsin Inhibits Breast Cancer Glucose Metabolism Reprogramming Based on Network Pharmacology and Molecular Docking. <i>Oncologie</i> , 2022, 24, 483-498.	0.2	1
1066	Current status of nanomedicine for breast cancer treatment. , 2022, , 65-110.		0
1067	Neoadjuvant Chemotherapy for Breast Cancer: Evolution of Clinical Practice in a French Cancer Center Over 16 Years and Pathologic Response Rates According to Tumor Subtypes and Clinical Tumor Size: Retrospective Cohort Study. <i>Journal of Surgery and Research</i> , 2022, 05, .	0.1	2
1068	Polymeric micelles for drug delivery in oncology with an emphasis on siRNA conveyance. , 2022, , 199-284.		0
1069	Preoperative Radiation. , 2022, , 303-310.		0
1070	Targeting Metastatic Disease: Challenges and New Opportunities. , 2022, , 51-68.		0
1071	Efficacy and safety of trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer: a single center study. <i>Iberoamerican Journal of Medicine</i> , 2022, 4, 191-198.	0.1	0
1072	The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review. , 2022, 39, .		6

#	ARTICLE	IF	CITATIONS
1073	Incidence and risk of severe adverse events associated with trastuzumab emtansine (T-DM1) in the treatment of breast cancer: an up-to-date systematic review and meta-analysis of randomized controlled clinical trials. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 1343-1350.	1.3	5
1074	Pretreatment platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as a predictor of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: single center experience from Turkey. <i>Anti-Cancer Drugs</i> , 2022, 33, 1150-1155.	0.7	4
1075	Breast cancer: an up-to-date review and future perspectives. <i>Cancer Communications</i> , 2022, 42, 913-936.	3.7	70
1076	From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
1078	Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	7
1079	Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	15
1080	Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer. <i>JAMA Surgery</i> , 2022, 157, 991.	2.2	32
1082	Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	15
1083	Breast Cancer in Geriatric Patients: Current Landscape and Future Prospects. <i>Clinical Interventions in Aging</i> , 0, Volume 17, 1445-1460.	1.3	10
1084	Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma. <i>Cancer Medicine</i> , 2023, 12, 3027-3035.	1.3	1
1085	Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer. <i>Annals of Translational Medicine</i> , 2022, 10, 1031-1031.	0.7	2
1086	Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO's pharmacovigilance database. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 1351-1361.	1.3	8
1087	Effect of Ado-Trastuzumab Emtansine on Autologous Platelet Kinetics and Function. <i>JCO Precision Oncology</i> , 2022, , .	1.5	1
1088	Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model. <i>Clinical Breast Cancer</i> , 2022, 22, 781-791.	1.1	1
1089	Current Molecular Combination Therapies Used for the Treatment of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11046.	1.8	19
1090	Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer. <i>JAMA Oncology</i> , 2022, 8, 1668.	3.4	15
1091	Emerging Targeted Therapies for Early Breast Cancer. <i>Drugs</i> , 2022, 82, 1437-1451.	4.9	5
1092	Breast Cancer Statistics, 2022. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 524-541.	157.7	611

#	ARTICLE	IF	CITATIONS
1093	Surgical Management of the Axilla in Breast Cancer: Evolving but Still Necessary. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	4
1094	Clinical N3 is an independent risk factor of recurrence for breast cancer patients achieving pathological complete response and near-pathological complete response after neoadjuvant chemotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1095	Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 0, 5, 971-80.	0.9	9
1096	NMR-Based Metabolomics to Evaluate Individual Response to Treatments. <i>Handbook of Experimental Pharmacology</i> , 2022, , 209-245.	0.9	4
1097	Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis. <i>Cancers</i> , 2022, 14, 5051.	1.7	8
1098	Is the TCH-P regimen active in early or locally advanced HER2-positive breast cancer? Results of a retrospective study. <i>Acta OncolÃ³gica</i> , 2022, 61, 1394-1399.	0.8	1
1099	Systemic therapy for early-stage breast cancer: learning from the past to build the future. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 763-774.	12.5	32
1100	Preoperative Systemic Therapy for Breast Cancer. <i>Surgical Clinics of North America</i> , 2023, 103, 201-217.	0.5	4
1101	Imaging of Drug-Related Pneumonitis in Oncology. <i>Seminars in Respiratory and Critical Care Medicine</i> , 0, , .	0.8	0
1102	Breast surgery after neoadjuvant chemotherapy: time for a change?. <i>Lancet Oncology</i> , The, 2022, 23, 1477-1479.	5.1	0
1103	Breast cancer image analysis using deep learning techniques â€“ a survey. <i>Health and Technology</i> , 2022, 12, 1133-1155.	2.1	1
1104	Resistance to Trastuzumab. <i>Cancers</i> , 2022, 14, 5115.	1.7	23
1106	Quantitative DCE-MRI prediction of breast cancer recurrence following neoadjuvant chemotherapy: a preliminary study. <i>BMC Medical Imaging</i> , 2022, 22, .	1.4	4
1110	Nomogram for Early Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Combining Both Clinicopathological and Imaging Indicators. <i>Current Problems in Cancer</i> , 2022, , 100914.	1.0	1
1111	Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy. <i>Breast</i> , 2022, 66, 199-203.	0.9	4
1112	Breast diseases. , 2023, , 311-344.e7.		0
1113	Innovative Approach for a Typology of Treatment Sequences in Early Stage HER2 Positive Breast Cancer Patients Treated With Trastuzumab in the French National Hospital Database. <i>Cancer Informatics</i> , 2022, 21, 117693512211351.	0.9	1
1114	Pharmacological profile - trastuzumab emtansine. <i>Onkologie (Czech Republic)</i> , 2022, 16, 273-275.	0.0	0

#	ARTICLE	IF	CITATIONS
1115	Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer. <i>Cancers</i> , 2022, 14, 5467.	1.7	4
1116	Antibody-Drug Conjugates and Tissue-Agnostic Drug Development. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 462-468.	1.0	0
1117	Surgical management of breast cancer in Victoria: A state-wide audit. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, , .	0.7	0
1118	Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. <i>Cancer Communications</i> , 2023, 43, 297-337.	3.7	18
1120	Whole Transcriptome Analysis of Breast Cancer Tumors during Neoadjuvant Chemotherapy: Association with Hematogenous Metastasis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13906.	1.8	1
1121	Strategies for Mitigating Antibody-Drug Conjugate Related Adverse Events for Precision Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 496-507.	1.0	1
1122	ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer. <i>Future Oncology</i> , 2022, 18, 3563-3572.	1.1	6
1123	Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 423-428.	1.0	4
1124	Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer. <i>Genes</i> , 2022, 13, 2065.	1.0	19
1125	Optimizing adjuvant and post-neoadjuvant therapy in HER2-positive early breast cancer. <i>Expert Review of Anticancer Therapy</i> , 0, , .	1.1	0
1126	Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100432.	0.6	0
1127	Targeting HER2-positive breast cancer: advances and future directions. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 101-126.	21.5	140
1128	The impact of neoadjuvant systemic treatment on postoperative complications in breast cancer surgery. <i>Breast Cancer Research and Treatment</i> , 2023, 197, 333-341.	1.1	1
1129	Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2+ breast cancer. <i>Breast Cancer Research and Treatment</i> , 2023, 197, 425-434.	1.1	1
1130	Recent advances in tumor biomarker detection by lanthanide upconversion nanoparticles. <i>Journal of Materials Chemistry B</i> , 2023, 11, 755-771.	2.9	2
1131	Current Standard Clinical Predictive Markers. , 2022, , 873-894.		0
1132	Three-year disease-free survival in randomized trials of neoadjuvant chemotherapy and HER2-targeted therapy in breast cancer: A meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 181, 103880.	2.0	0
1133	Acute skin radiation toxicity seen with concurrent T-DM1: A single institutional report of 35 patients. <i>Breast</i> , 2023, 67, 26-29.	0.9	3

#	ARTICLE	IF	CITATIONS
1134	Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2023, 37, 103-115.	0.9	1
1135	Multidisciplinary Management of Brain Metastasis from Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2023, 37, 183-202.	0.9	1
1136	Surgical Management of the Axilla for Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2023, 37, 51-77.	0.9	4
1137	An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs. <i>Cancer Letters</i> , 2023, 554, 216024.	3.2	4
1138	Breast cancer radiation therapy: A bibliometric analysis of the scientific literature. <i>Clinical and Translational Radiation Oncology</i> , 2023, 39, 100556.	0.9	8
1139	Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly. <i>Journal of Breast Cancer</i> , 0, 25, .	0.8	0
1140	Special Clinical Settings: Tumors Arising in Pregnancy, Pregnancy-Like (Pseudolactational) Proliferations, Breast Carcinoma in the Pre-neoadjuvant Chemotherapy Setting, Recurrent Breast Carcinoma, and Inflammatory Breast Carcinoma. , 2022, , 825-871.		0
1141	Antibody-Drug Conjugates in Breast Cancer: Searching for Magic Bullets. <i>Journal of Clinical Oncology</i> , 2023, 41, 732-735.	0.8	1
1142	Preoperative Computed Tomography Radiomics Analysis for Predicting Receptors Status and Ki-67 Levels in Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 526-533.	0.6	5
1143	Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial. <i>Clinical Cancer Research</i> , 2023, 29, 532-540.	3.2	11
1144	Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 1341-1355.	1.0	22
1145	The evolving therapeutic landscape of antibody-“drug conjugates in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1325-1331.	1.1	1
1146	Staging Breast Cancer with MRI, the T. A Key Role in the Neoadjuvant Setting. <i>Cancers</i> , 2022, 14, 5786.	1.7	8
1147	Definitive Radiation With Nodal Boost for Patients With Locally Advanced Breast Cancer. <i>Practical Radiation Oncology</i> , 2022, , .	1.1	1
1149	Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 14, 417-432.	1.0	1
1150	Biomarker Discordances and Alterations Observed in Breast Cancer Treated with Neoadjuvant Chemotherapy: Causes, Frequencies, and Clinical Significances. <i>Current Oncology</i> , 2022, 29, 9695-9710.	0.9	3
1151	Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm?. <i>Journal of Clinical Medicine</i> , 2022, 11, 7239.	1.0	6
1153	Expanding the reach of HER2-targeted therapies: transformation of an historical paradigm. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	0

#	ARTICLE	IF	CITATIONS
1154	A phase II single-arm study of palbociclib in patients with HER2-positive breast cancer with brain metastases and analysis of ctDNA in patients with active brain metastases. <i>Clinical Breast Cancer</i> , 2022, , .	1.1	4
1155	Effect of the HER-2/CEP17 ratio in IHC 2+/FISH-amplified breast cancer on pathological complete response to neoadjuvant pertuzumab and trastuzumab treatment—a retrospective cohort study. <i>Gland Surgery</i> , 2022, 11, 1887-1896.	0.5	0
1156	Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	12
1157	Neoadjuvant immunotherapy for resectable esophageal cancer: A review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1158	A second-generation antibody–drug conjugate to treat HER2-positive breast cancer. <i>Lancet, The</i> , 2023, 401, 80-81.	6.3	2
1159	Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1721-1731.	1.3	7
1160	Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer. <i>Journal of Immunotherapy and Precision Oncology</i> , 2023, 6, 1-9.	0.6	1
1161	Association of Endocrine Therapy for HR+/ <i>ERBB2</i> + Metastatic Breast Cancer With Survival Outcomes. <i>JAMA Network Open</i> , 2022, 5, e2247154.	2.8	0
1162	Pathology of neoadjuvant therapy and immunotherapy testing for breast cancer. <i>Histopathology</i> , 2023, 82, 170-188.	1.6	5
1163	Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends. <i>Cancers</i> , 2023, 15, 51.	1.7	6
1164	Borderline indications for ovarian suppression: addressing uncertainties with patients. <i>Future Oncology</i> , 0, , .	1.1	0
1166	COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy. <i>ESMO Open</i> , 2022, 7, 100637.	2.0	6
1167	Additional effect of anthracycline in preoperative chemotherapy with a sequential anthracycline–containing regimen preceded by pertuzumab, trastuzumab and docetaxel combination therapy. <i>Experimental and Therapeutic Medicine</i> , 2022, 25, .	0.8	0
1168	The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2023, 113, 102500.	3.4	15
1169	Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated <i>ERBB2</i> (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases. <i>JAMA Oncology</i> , 2023, 9, 197.	3.4	40
1170	Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Current Oncology</i> , 2022, 29, 9891-9895.	0.9	2
1171	Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage <i>ERBB2</i> /HER2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2023, 9, 490.	3.4	11
1172	Novel Implications of Prognostic Markers to Monitor the Disease: An Overview. , 2023, , 182-197.		0

#	ARTICLE	IF	CITATIONS
1174	Breast cancer heterogeneity and its implication in personalized precision therapy. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	31
1175	Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine+pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE). <i>Breast Cancer Research</i> , 2023, 25, .	2.2	6
1176	Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1177	Comparison of automated breast volume scanning with conventional ultrasonography, mammography, and MRI to assess residual breast cancer after neoadjuvant therapy by molecular type. <i>Clinical Radiology</i> , 2023, , .	0.5	0
1178	Optimizing postoperative outcomes following neoadjuvant chemotherapy and mastectomy with immediate reconstruction: A national analysis. <i>Journal of Surgical Oncology</i> , 2023, 127, 768-775.	0.8	2
1179	The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2023, 6, 45-58.	0.9	3
1180	Antibody-drug conjugates in lung cancer: dawn of a new era?. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	21
1181	Exosome-Based Smart Drug Delivery Tool for Cancer Theranostics. <i>ACS Biomaterials Science and Engineering</i> , 2023, 9, 577-594.	2.6	57
1182	Systemic treatments for breast cancer brain metastasis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1183	Recommendations for the diagnosis and treatment of patients with early breast cancer: update 2023. <i>Current Opinion in Obstetrics and Gynecology</i> , 2023, 35, 67-72.	0.9	6
1184	Multimodality Imaging Review of HER2-positive Breast Cancer and Response to Neoadjuvant Chemotherapy. <i>Radiographics</i> , 2023, 43, .	1.4	3
1185	Molecular Pathways and Mechanisms of HER2 in Cancer Therapy. <i>Clinical Cancer Research</i> , 2023, 29, 2351-2361.	3.2	2
1186	HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1. <i>Journal of the National Cancer Institute</i> , 2023, 115, 332-336.	3.0	6
1187	Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer. <i>Cancers</i> , 2023, 15, 96.	1.7	2
1188	Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2023, 55, 101795.	3.2	7
1189	Impacts of HER2 immunohistochemical scores on response and outcomes of HER2-positive breast cancers after neoadjuvant therapy. <i>Journal of the Chinese Medical Association</i> , 2023, 86, 409-417.	0.6	5
1190	Real-life analysis of neoadjuvant-therapy-associated benefits for pathological complete response and survival in early breast cancer patients - role of trastuzumab in HER2+ BC and platinum in TNBC. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1191	End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1

#	ARTICLE	IF	CITATIONS
1192	Review of the status of neoadjuvant therapy in HER2-positive breast cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	5
1193	Clinicopathologic characteristics and prognostic significance of HER2-low expression in patients with early breast cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	4
1194	Timing of Chemotherapy and Patient-Reported Outcomes After Breast-Conserving Surgery and Mastectomy with Immediate Reconstruction. <i>Annals of Surgical Oncology</i> , 2023, 30, 2897-2909.	0.7	2
1195	Predictors of nodal metastases in early stage HER2+ breast cancer: Deciding on treatment approach with neoadjuvant chemotherapy vs. upfront surgery. <i>European Journal of Surgical Oncology</i> , 2023, 49, 1411-1416.	0.5	3
1196	Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate. <i>Pharmaceutics</i> , 2023, 15, 1242.	2.0	5
1197	Tailoring Treatment for Patients with Inflammatory Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2023, 24, 580-593.	1.3	8
1198	The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2023, 37, 513-531.	0.9	2
1199	Tailored axillary surgery – A novel concept for clinically node positive breast cancer. <i>Breast</i> , 2023, 69, 281-289.	0.9	6
1200	Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer. <i>Annals of Diagnostic Pathology</i> , 2023, 64, 152125.	0.6	2
1201	Pathologic response and residual tumor cellularity after neo-adjuvant chemotherapy predict prognosis in breast cancer patients. <i>Breast</i> , 2023, 69, 323-329.	0.9	8
1202	Future potential targets of antibody-drug conjugates in breast cancer. <i>Breast</i> , 2023, 69, 312-322.	0.9	2
1203	Real de-escalation or escalation in disguise?. <i>Breast</i> , 2023, 69, 249-257.	0.9	6
1204	Current Updates in Management of HER2-Positive and HER2-Low Breast Cancer. <i>Current Breast Cancer Reports</i> , 2023, 15, 135-141.	0.5	1
1205	Surgical management of locally advanced breast cancer: Recommendations of the Brazilian Society of Surgical Oncology. <i>Journal of Surgical Oncology</i> , 2022, 126, 57-67.	0.8	1
1206	Precision medicine in early breast cancer – beginning of a successful story?. <i>ESMO Open</i> , 2023, 8, 100780.	2.0	0
1207	HER2 Positive Breast Cancer Therapy - A Challenging and Continuously Moving Pathway – A Narrative Literature Review. <i>Archives of Breast Cancer</i> , 2023, 10, 15-25.	0.0	0
1208	Antibody-Drug Conjugates in Prostate Cancer: A Systematic Review. <i>Cureus</i> , 2023, , .	0.2	1
1209	Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 1569-1581.	3.2	8

#	ARTICLE	IF	CITATIONS
1210	The optimal timing between neoadjuvant therapy and surgery of breast cancer: A brief systematic review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 183, 103921.	2.0	1
1211	A Real-World Data Retrospective Cohort Study of HER2-positive, Early-Stage Breast Cancer in Patients 70 Years of Age or Older: Natural History, Treatment Patterns, and Outcomes. <i>Clinical Breast Cancer</i> , 2023, , .	1.1	0
1212	Volume change rate before and after neoadjuvant systemic therapy of breast cancer is an efficacious evaluation index to predict pathological complete response. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1213	Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial. <i>European Journal of Cancer</i> , 2023, 184, 48-59.	1.3	8
1214	HER2 Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3590.	1.8	3
1215	Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer. <i>Egyptian Heart Journal</i> , 2023, 75, .	0.4	0
1216	Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC). <i>Journal of Clinical Medicine</i> , 2023, 12, 1524.	1.0	11
1217	ASO Author Reflections: Sequencing of Breast Surgery and Chemotherapy Does Not Impact Patient-Reported Outcomes. <i>Annals of Surgical Oncology</i> , 2023, 30, 2910-2911.	0.7	0
1219	Prognostic analysis of three forms of Kiâ€67 in patients with breast cancer with nonâ€pathological complete response before and after neoadjuvant systemic treatment. <i>Cancer Medicine</i> , 2023, 12, 9363-9372.	1.3	4
1220	Recent Advances in Optimizing Radiation Therapy Decisions in Early Invasive Breast Cancer. <i>Cancers</i> , 2023, 15, 1260.	1.7	8
1221	Mechanisms of Resistance to Antibodyâ€Drug Conjugates. <i>Cancers</i> , 2023, 15, 1278.	1.7	10
1223	De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 3796-3804.	0.8	7
1224	Single molecule RNA in situ detection in clinical FFPE tissue sections by vsmCISH. <i>Rna</i> , 0, , rna.079482.122.	1.6	0
1225	Breast cancer patient-derived explant cultures recapitulate in vivo drug responses. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
1226	Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	1
1227	Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution. <i>Cancers</i> , 2023, 15, 1385.	1.7	5
1228	Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study. <i>Journal of Medical Economics</i> , 2023, 26, 394-402.	1.0	3
1229	Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer. <i>Cancers</i> , 2023, 15, 1413.	1.7	4

#	ARTICLE	IF	CITATIONS
1230	Surgical Planning after Neoadjuvant Treatment in Breast Cancer: A Multimodality Imaging-Based Approach Focused on MRI. <i>Cancers</i> , 2023, 15, 1439.	1.7	2
1231	Visualizing the distribution of flavonoids in litchi (<i>Litchi chinensis</i>) seeds through matrix-assisted laser desorption/ionization mass spectrometry imaging. <i>Frontiers in Plant Science</i> , 0, 14, .	1.7	1
1232	Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within breast cancer subtypes and stages among older women: a SEER-Medicare analysis. <i>Breast Cancer</i> , 2023, 30, 489-496.	1.3	1
1233	A Case of Hereditary Spherocytosis in a Patient who Received Chemotherapy Safely after Splenectomy. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2022, 83, 1403-1406.	0.0	0
1235	Advances in understanding the role and mechanisms of tumor stem cells in HER2-positive breast cancer treatment resistance (Review). <i>International Journal of Oncology</i> , 2023, 62, .	1.4	3
1236	Optimizing treatment for HER2-positive HR-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2023, 115, 102529.	3.4	2
1237	Advances in Breast Cancer Screening: Precision, Imaging, and Harms. , 2023, , 1-27.		0
1238	Time to Surgery in Breast Cancer—Is Faster Always Better?. <i>JAMA Surgery</i> , 2023, 158, 492.	2.2	1
1239	Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer. <i>Journal of the National Cancer Center</i> , 2023, 3, 121-128.	3.0	1
1240	Favorable Outcome and Safety of Neoadjuvant Trastuzumab Emtansine (T-DM1) in a HER2-Positive Early Breast Cancer Patient with Severe Renal Disease on Hemodialysis Ineligible for Conventional Chemotherapy: A Case Report. <i>Reports</i> , 2023, 6, 13.	0.2	0
1241	Targeted Two-Step Delivery of Oncotheranostic Nano-PLGA for HER2-Positive Tumor Imaging and Therapy In Vivo: Improved Effectiveness Compared to One-Step Strategy. <i>Pharmaceutics</i> , 2023, 15, 833.	2.0	6
1242	Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2023, 23, 436-446.	1.1	2
1243	Incidence of antibody–drug conjugates-related pneumonitis in patients with solid tumors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 184, 103960.	2.0	3
1244	The use of neoadjuvant systemic therapies in breast cancer in Australia and New Zealand: Breast Surgeons of Australia and New Zealand quality audit. <i>ANZ Journal of Surgery</i> , 2023, 93, 889-895.	0.3	0
1246	Immunotherapy for HER-2 positive breast cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	8
1247	Integrating antibody drug conjugates in the management of gynecologic cancers. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 420-429.	1.2	8
1248	Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	0
1249	What Is Known about Breast Cancer in Young Women?. <i>Cancers</i> , 2023, 15, 1917.	1.7	18

#	ARTICLE	IF	CITATIONS
1250	Impact of residual disease biomarkers on the prognosis of <sc>HER2</sc>-positive breast cancer following neoadjuvant therapy. <i>Cancer Medicine</i> , 2023, 12, 11293-11304.	1.3	2
1251	Phytochemical-based nanodrugs going beyond the state-of-the-art in cancer management—Targeting cancer stem cells in the framework of predictive, preventive, personalized medicine. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	5
1252	Nodal positivity and systemic therapy among patients with clinical T1â€T2N0 human epidermal growth factor receptorâ€positive breast cancer: Results from two international cohorts. <i>Cancer</i> , 2023, 129, 1836-1845.	2.0	5
1254	Antibodyâ€Drug Conjugate Revolution in Breast Cancer: The Road Ahead. <i>Current Treatment Options in Oncology</i> , 2023, 24, 442-465.	1.3	6
1255	Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy. <i>Cardio-Oncology</i> , 2023, 9, .	0.8	2
1256	Emerging Targeted Therapies for HER2-Positive Breast Cancer. <i>Cancers</i> , 2023, 15, 1987.	1.7	18
1257	Incidence and prognostic impact of <sc>HER2</sc>-positivity loss after dual <sc>HER2</sc>-directed neoadjuvant therapy for <sc>HER2</sc>+ breast cancer. <i>Cancer Medicine</i> , 2023, 12, 10647-10659.	1.3	3
1258	A prospective cohort study identifying radiologic and tumor related factors of importance for breast conserving surgery after neoadjuvant chemotherapy. <i>European Journal of Surgical Oncology</i> , 2023, , .	0.5	0
1259	Co-Clinical Study of [fam-] Trastuzumab Deruxtecan (DS8201a) in Patient-Derived Xenograft Models of Uterine Carcinosarcoma and Its Association with Clinical Efficacy. <i>Clinical Cancer Research</i> , 2023, 29, 2239-2249.	3.2	4
1260	Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2â€Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Antiâ€Human Epidermal Growth Factor Receptor 2 Therapy. <i>Journal of Clinical Oncology</i> , 2023, 41, 2988-2997.	0.8	13
1261	Predicting Pathological Complete Response in Breast Cancer After Two Cycles of Neoadjuvant Chemotherapy by Tumor Reduction Rate: A Retrospective Case-Control Study. <i>Journal of Breast Cancer</i> , 0, 26, .	0.8	0
1262	Realâ€world data indicated that neoadjuvant chemotherapy alone was associated with a higher risk of tumor recurrence in highâ€risk breast cancer subgroup patients. <i>Oncology Letters</i> , 2023, 25, .	0.8	0
1263	Individualizing Curative-Intent Therapy in HER2-Positive Early-Stage Breast Cancer. <i>Current Treatment Options in Oncology</i> , 0, , .	1.3	0
1264	Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy. <i>Journal of Breast Cancer</i> , 0, 26, .	0.8	1
1265	The tumor-nerve circuit in breast cancer. <i>Cancer and Metastasis Reviews</i> , 2023, 42, 543-574.	2.7	4
1266	The Future of Breast Cancer Research in the Survivorship Field. <i>Oncology and Therapy</i> , 2023, 11, 199-229.	1.0	4
1267	Compliance to adjuvant endocrine therapy and survival in breast cancer patients.. <i>Cancer Treatment and Research Communications</i> , 2023, 35, 100704.	0.7	1
1269	St. Gallen/Vienna 2023: Optimization of Treatment for Patients with Primary Breast Cancer â€ A Brief Summary of the Consensus Discussion. <i>Breast Care</i> , 2023, 18, 213-222.	0.8	7

#	ARTICLE	IF	CITATIONS
1270	Antibody Drug Conjugates. , 0, , .		0
1271	Post-mastectomy radiation therapy in HER-2 positive breast cancer after primary systemic therapy: Pooled analysis of TRYPHAENA and NeoSphere trials. <i>Radiotherapy and Oncology</i> , 2023, 184, 109668.	0.3	3
1272	Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy. <i>Npj Breast Cancer</i> , 2023, 9, .	2.3	6
1273	Correlation of Mammographic Microcalcifications with Final Surgical Pathology After Neoadjuvant Chemotherapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	0
1274	Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis. <i>European Journal of Cancer</i> , 2023, 190, 112885.	1.3	5
1275	Breast Cancer Recurrence by Subtype in a Diverse, Contemporary Cohort of Young Women. <i>Journal of the American College of Surgeons</i> , 2023, 237, 13-23.	0.2	1
1276	Axillary pathologic response after neoadjuvant chemotherapy and surgery according to breast cancers subtypes and survival impact. <i>Bulletin Du Cancer</i> , 2023, , .	0.6	3
1277	High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 685-696.	1.0	1
1278	Biopsy-Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	1
1279	Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-“Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2”-Positive Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2023, 41, 2998-3008.	0.8	14
1280	“Targeting”™ Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer”An Updated Review. <i>Current Oncology</i> , 2023, 30, 4329-4350.	0.9	1
1281	Understanding the activity of antibody-“drug conjugates in primary and secondary brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 372-389.	12.5	18
1282	Neoadjuvant chemotherapy in non-metastatic breast cancer: The surgeon's perspective. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2023, 21, 356-360.	0.8	2
1330	Combining radiation and systemic therapy. , 2024, , 99-126.		0
1358	Letter to the Editor Regarding “Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single Agent Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in the United States” Advances in Therapy, 0, , .	1.3	0
1369	Management of Breast Cancer. , 2023, , 17-31.		0
1411	Molecular testing in breast cancer. , 2024, , 303-318.		0
1448	Sentinel Lymph Node Biopsy (SLNB) Post-NACT and Targeted Axillary Dissection (TAD). , 2023, , 115-124.		0

#	ARTICLE	IF	CITATIONS
1489	Adjuvant Systemic Treatment in Early Breast Cancer. , 2023, , 275-286.		0
1490	Evidence-Based Practice in Multidisciplinary Breast Cancer Management. , 2023, , 411-432.		0
1504	A Review of the Current FDA-Approved Antibody-Drug Conjugates: Landmark Clinical Trials and Indications. Pharmaceutical Medicine, 0, , .	1.0	1
1510	Applied Aspects of Systemic Therapy in Breast Oncoplasty and Reconstruction. , 2023, , 57-64.		0
1511	Management Approach to Recurrence Following Oncoplastic Breast Surgery. , 2023, , 271-281.		0
1522	(Neo)adjuvant approaches: pavement on the road to cure”breast cancer. Memo - Magazine of European Medical Oncology, 2024, 17, 6-9.	0.3	1
1529	Assessment and Response to Neoadjuvant Treatments in Breast Cancer: Current Practice, Response Monitoring, Future Approaches and Perspectives. Cancer Treatment and Research, 2023, , 105-147.	0.2	0
1530	Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer. Cancer Treatment and Research, 2023, , 237-281.	0.2	0
1541	Estimating the Benefit of Preoperative Systemic Therapy to Reduce the Extent of Breast Cancer Surgery: Current Standard and Future Directions. Cancer Treatment and Research, 2023, , 149-174.	0.2	0
1542	New Concepts in Cardio-Oncology. Cancer Treatment and Research, 2023, , 303-341.	0.2	0
1543	Breast Cancer Brain Metastases: Achilles” Heel in Breast Cancer Patients” Care. Cancer Treatment and Research, 2023, , 283-302.	0.2	0
1546	OS benefit of adjuvant T-DM1 in early breast cancer with residual disease after neoadjuvant therapy. , 0, , .		0
1551	Axillary nodal staging in breast cancer: what have we learned?. Clinical and Experimental Metastasis, 0, , .	1.7	0
1576	Trastuzumab for Active Targeting in Cancer Therapy. , 2024, , 1-30.		0
1589	Case report: Successful treatment of a rare HER2-positive advanced breast squamous cell carcinoma. Frontiers in Pharmacology, 0, 15, .	1.6	0